{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:46:07Z","timestamp":1790318767491,"version":"4.1.0"},"reference-count":383,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03535-7","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T07:28:37Z","timestamp":1758007717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7504-4516","authenticated-orcid":false,"given":"Farhan","family":"Ikhtiar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-5566","authenticated-orcid":false,"given":"Adil","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0940-2356","authenticated-orcid":false,"given":"Syed M. Safeer Mehdi","family":"Bokhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"issue":"4","key":"3535_CR1","first-page":"410","volume":"130","author":"J Taylor","year":"2017","unstructured":"Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. J Am Soc Hematol. 2017;130(4):410\u201323.","journal-title":"J Am Soc Hematol"},{"issue":"2","key":"3535_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00002820-200603000-00012","volume":"29","author":"M-L Yeh","year":"2006","unstructured":"Yeh M-L, Lee T-I, Chen H-H, Chao T-Y. The influences of Chan-Chuang qi-gong therapy on complete blood cell counts in breast cancer patients treated with chemotherapy. Cancer Nurs. 2006;29(2):149\u201355.","journal-title":"Cancer Nurs"},{"issue":"5","key":"3535_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ajh.26503","volume":"97","author":"DA Arber","year":"2022","unstructured":"Arber DA, Hasserjian RP, Orazi A, Mathews V, Roberts AW, Schiffer CA, et al. Classification of myeloid neoplasms\/acute leukemia: global perspectives and the international consensus classification approach. Am J Hematol. 2022;97(5):514.","journal-title":"Am J Hematol"},{"issue":"20","key":"3535_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015441","volume":"24","author":"L Boucher","year":"2023","unstructured":"Boucher L, Sorel N, Desterke C, Chollet M, Rozalska L, Gallego Hernanz MP, et al. Deciphering potential molecular signatures to differentiate acute myeloid leukemia (AML) with BCR::ABL1 from chronic myeloid leukemia (CML) in blast crisis. Int J Mol Sci. 2023;24(20):15441.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3535_CR5","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1097\/HS9.0000000000000536","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, et al. Precision medicine in hematology 2021: definitions, tools, perspectives, and open questions. Hemasphere. 2021;5(3):e536.","journal-title":"Hemasphere"},{"issue":"1","key":"3535_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13039-025-00712-9","volume":"18","author":"C Lauzon-Young","year":"2025","unstructured":"Lauzon-Young C, Silva A, Sadikovic B. Epigenomic insights and computational advances in hematologic malignancies. Mol Cytogenet. 2025;18(1):9.","journal-title":"Mol Cytogenet"},{"issue":"7","key":"3535_CR7","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.ajpath.2016.02.023","volume":"186","author":"BV Chakravarthi","year":"2016","unstructured":"Chakravarthi BV, Nepal S, Varambally S. Genomic and epigenomic alterations in cancer. Am J Pathol. 2016;186(7):1724\u201335.","journal-title":"Am J Pathol"},{"issue":"5","key":"3535_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","volume":"10","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267\u201376.","journal-title":"Nat Rev Clin Oncol"},{"key":"3535_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-017-0625-2","volume":"19","author":"JL Messerschmidt","year":"2017","unstructured":"Messerschmidt JL, Bhattacharya P, Messerschmidt GL. Cancer clonal theory, immune escape, and their evolving roles in cancer multi-agent therapeutics. Curr Oncol Rep. 2017;19:1\u201311.","journal-title":"Curr Oncol Rep"},{"key":"3535_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-017-0900-y","volume":"15","author":"DR Caswell","year":"2017","unstructured":"Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med. 2017;15:1\u20139.","journal-title":"BMC Med"},{"issue":"12","key":"3535_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"J-C Marine","year":"2020","unstructured":"Marine J-C, Dawson S-J, Dawson MA. Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020;20(12):743\u201356.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"3535_CR12","first-page":"5377","volume":"7","author":"WD Cleanclay","year":"2023","unstructured":"Cleanclay WD, Zakari S, Adigun TO, Ayeni TO, Nnaji PC, Nnenna AD, et al. Cancer Biology and Therapeutics: Navigating Recent Advances and Charting Future Directions. Trop J Nat Prod Res. 2023;7(12):5377\u2013402.","journal-title":"Trop J Nat Prod Res"},{"issue":"2","key":"3535_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/joim.13508","volume":"292","author":"T W\u00e4sterlid","year":"2022","unstructured":"W\u00e4sterlid T, Cavelier L, Haferlach C, Konopleva M, Fr\u00f6hling S, \u00d6stling P, et al. Application of precision medicine in clinical routine in haematology\u2014challenges and opportunities. J Intern Med. 2022;292(2):243\u201361.","journal-title":"J Intern Med"},{"key":"3535_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1527600","volume":"11","author":"E Youssef","year":"2025","unstructured":"Youssef E, Fletcher B, Palmer D. Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology. Front Med. 2025;11:1527600.","journal-title":"Front Med"},{"issue":"12","key":"3535_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201902552","volume":"7","author":"X Dai","year":"2020","unstructured":"Dai X, Blancafort P, Wang P, Sgro A, Thompson EW, Ostrikov K. Innovative precision gene-editing tools in personalized cancer medicine. Adv Sci. 2020;7(12):1902552.","journal-title":"Adv Sci"},{"issue":"8","key":"3535_CR16","first-page":"487","volume":"34","author":"S Mukherjee","year":"2019","unstructured":"Mukherjee S. Genomics-guided immunotherapy for precision medicine in cancer. Cancer Biother Radiopharm. 2019;34(8):487\u201397.","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"3535_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.oraloncology.2006.03.014","volume":"43","author":"S Sonis","year":"2007","unstructured":"Sonis S, Haddad R, Posner M, Watkins B, Fey E, Morgan T, et al. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol. 2007;43(3):289\u2013300.","journal-title":"Oral Oncol"},{"issue":"9","key":"3535_CR18","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/ijc.21962","volume":"119","author":"B Strahm","year":"2006","unstructured":"Strahm B, Malkin D. Hereditary cancer predisposition in children: genetic basis and clinical implications. Int J Cancer. 2006;119(9):2001\u20136.","journal-title":"Int J Cancer"},{"issue":"2","key":"3535_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0039-6109(05)70194-8","volume":"80","author":"MG Alvarez","year":"2000","unstructured":"Alvarez MG, Besa PC. Molecular basis of cancer and clinical applications. Surg Clin North Am. 2000;80(2):443\u201357.","journal-title":"Surg Clin North Am"},{"issue":"9","key":"3535_CR20","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1080\/10428194.2021.1894652","volume":"62","author":"S Adnan-Awad","year":"2021","unstructured":"Adnan-Awad S, Kankainen M, Mustjoki S. Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia. Leuk Lymphoma. 2021;62(9):2064\u201378.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"3535_CR21","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/bloodadvances.2020003541","volume":"5","author":"SR Bohl","year":"2021","unstructured":"Bohl SR, Schmalbrock LK, Bauhuf I, Meyer T, Dolnik A, Szyska M, et al. Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. Blood Adv. 2021;5(9):2391\u2013402.","journal-title":"Blood Adv"},{"key":"3535_CR22","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.omtm.2020.06.022","volume":"18","author":"MP Ernst","year":"2020","unstructured":"Ernst MP, Broeders M, Herrero-Hernandez P, Oussoren E, van der Ploeg AT, Pijnappel WP. Ready for repair? Gene editing enters the clinic for the treatment of human disease. Mol Therapy Methods Clin Dev. 2020;18:532\u201357.","journal-title":"Mol Therapy Methods Clin Dev"},{"key":"3535_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-025-10857-0","author":"M Bolideei","year":"2025","unstructured":"Bolideei M, Barzigar R, Gahrouei RB, Mohebbi E, Haider KH, Paul S, et al. Applications of gene editing and nanotechnology in stem cell-based therapies for human diseases. Stem Cell Reviews Rep. 2025. https:\/\/doi.org\/10.1007\/s12015-025-10857-0.","journal-title":"Stem Cell Reviews Rep"},{"key":"3535_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0746-1","volume":"12","author":"H Wang","year":"2019","unstructured":"Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12:1\u201320.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"3535_CR25","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","volume":"50","author":"R Kaur","year":"2023","unstructured":"Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50(11):9663\u201376.","journal-title":"Mol Biol Rep"},{"key":"3535_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.763790","volume":"11","author":"Y Peng","year":"2021","unstructured":"Peng Y, Mei W, Ma K, Zeng C. Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives. Front Oncol. 2021;11:763790.","journal-title":"Front Oncol"},{"issue":"6","key":"3535_CR27","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.3892\/or.2013.2734","volume":"30","author":"D-S Wu","year":"2013","unstructured":"Wu D-S, Shen J-Z, Yu A-F, Fu H-Y, Zhou H-R, Shen S-F. Epigallocatechin-3-gallate and trichostatin A synergistically inhibit human lymphoma cell proliferation through epigenetic modification of p16INK4a. Oncol Rep. 2013;30(6):2969\u201375.","journal-title":"Oncol Rep"},{"issue":"3","key":"3535_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/cbdd.13801","volume":"97","author":"J Liu","year":"2021","unstructured":"Liu J, Zhang Y, Huang H, Lei X, Tang G, Cao X, et al. Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation. Chem Biol Drug Des. 2021;97(3):649\u201364.","journal-title":"Chem Biol Drug Des"},{"issue":"6","key":"3535_CR29","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"3535_CR30","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/PAS.0000000000001834","volume":"46","author":"C Laurent","year":"2022","unstructured":"Laurent C, Syrykh C, Hamon M, Ad\u00e9la\u00efde J, Guille A, Escudi\u00e9 F, et al. Resistance of B-cell lymphomas to CAR T-cell therapy is associated with genomic tumor changes which can result in transdifferentiation. Am J Surg Pathol. 2022;46(6):742\u201353.","journal-title":"Am J Surg Pathol"},{"key":"3535_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01237","volume":"9","author":"J Cheng","year":"2019","unstructured":"Cheng J, Zhao L, Zhang Y, Qin Y, Guan Y, Zhang T, et al. Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. Front Oncol. 2019;9:1237.","journal-title":"Front Oncol"},{"issue":"5","key":"3535_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050354","volume":"11","author":"W Lattanzi","year":"2021","unstructured":"Lattanzi W, Ripoli C, Greco V, Barba M, Iavarone F, Minucci A, et al. Basic and preclinical research for personalized medicine. J Pers Med. 2021;11(5):354.","journal-title":"J Pers Med"},{"key":"3535_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-821972-0.00009-5","volume-title":"Advanced biotechnology-based therapeutics","author":"S Ravichandran","year":"2021","unstructured":"Ravichandran S, Verma G. Advanced biotechnology-based therapeutics. Elsevier: Translational Biotechnology. Elsevier; 2021. https:\/\/doi.org\/10.1016\/B978-0-12-821972-0.00009-5."},{"issue":"6","key":"3535_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.colegn.2016.10.009","volume":"24","author":"S Breen","year":"2017","unstructured":"Breen S, Kofoed S, Ritchie D, Dryden T, Maguire R, Kearney N, et al. Remote real-time monitoring for chemotherapy side-effects in patients with blood cancers. Collegian. 2017;24(6):541\u20139.","journal-title":"Collegian"},{"issue":"3","key":"3535_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2174\/0115665232275754231204072320","volume":"24","author":"DK Chanchal","year":"2024","unstructured":"Chanchal DK, Chaudhary JS, Kumar P, Agnihotri N, Porwal P. CRISPR-based therapies: revolutionizing drug development and precision medicine. Curr Gene Ther. 2024;24(3):193\u2013207.","journal-title":"Curr Gene Ther"},{"issue":"1","key":"3535_CR36","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev-cancerbio-050216-122035","volume":"2","author":"ER Mardis","year":"2018","unstructured":"Mardis ER. Insights from large-scale cancer genome sequencing. Annual Rev Cancer Biology. 2018;2(1):429\u201344.","journal-title":"Annual Rev Cancer Biology"},{"key":"3535_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.humgen.2024.201297","author":"M Dara","year":"2024","unstructured":"Dara M, Dianatpour M, Azarpira N, Omidifar N. Convergence of CRISPR and artificial intelligence: a paradigm shift in biotechnology. Hum Gene. 2024. https:\/\/doi.org\/10.1016\/j.humgen.2024.201297.","journal-title":"Hum Gene"},{"issue":"1","key":"3535_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03765-1","volume":"20","author":"AA Bhat","year":"2022","unstructured":"Bhat AA, Nisar S, Mukherjee S, Saha N, Yarravarapu N, Lone SN, et al. Integration of CRISPR\/Cas9 with artificial intelligence for improved cancer therapeutics. J Transl Med. 2022;20(1):534.","journal-title":"J Transl Med"},{"issue":"4","key":"3535_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215\u201329.","journal-title":"Nat Rev Clin Oncol"},{"key":"3535_CR40","doi-asserted-by":"publisher","first-page":"1462697","DOI":"10.3389\/fimmu.2024.1462697","volume":"15","author":"M Amiri","year":"2024","unstructured":"Amiri M, Moaveni AK, Majidi Zolbin M, Shademan B, Nourazarian A. Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR\/Cas9. Front Immunol. 2024;15:1462697.","journal-title":"Front Immunol"},{"issue":"12","key":"3535_CR41","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.humimm.2018.09.007","volume":"79","author":"H Mollanoori","year":"2018","unstructured":"Mollanoori H, Shahraki H, Rahmati Y, Teimourian S. CRISPR\/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Hum Immunol. 2018;79(12):876\u201382.","journal-title":"Hum Immunol"},{"issue":"1","key":"3535_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21(1):78.","journal-title":"Mol Cancer"},{"issue":"39","key":"3535_CR43","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1038\/sj.onc.1208979","volume":"24","author":"GP Taylor","year":"2005","unstructured":"Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia\/lymphoma and approaches to therapy. Oncogene. 2005;24(39):6047\u201357.","journal-title":"Oncogene"},{"key":"3535_CR44","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68161","author":"PP Tawde","year":"2024","unstructured":"Tawde PP, Choudhari SG, Syed ZQ, Gaidhane A. Rudolf virchow: integrating medicine and social reform for public health. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.68161.","journal-title":"Cureus"},{"issue":"21","key":"3535_CR45","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita","year":"2008","unstructured":"DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643\u201353.","journal-title":"Cancer Res"},{"issue":"1","key":"3535_CR46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","volume":"13","author":"N Zhang","year":"2023","unstructured":"Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13(1):82.","journal-title":"Blood Cancer J"},{"issue":"7","key":"3535_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1542\/pir.2018-0192","volume":"40","author":"JA Kaplan","year":"2019","unstructured":"Kaplan JA. Leukemia in children. Pediatr Rev. 2019;40(7):319\u201331.","journal-title":"Pediatr Rev"},{"issue":"4","key":"3535_CR48","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9(4):465\u201372.","journal-title":"JAMA Oncol"},{"issue":"2","key":"3535_CR49","first-page":"489","volume":"90","author":"DG Tenen","year":"1997","unstructured":"Tenen DG, Hromas R, Licht JD, Zhang D-E. Transcription factors, normal myeloid development, and leukemia. Blood J Am Soc Hematol. 1997;90(2):489\u2013519.","journal-title":"Blood J Am Soc Hematol"},{"issue":"2","key":"3535_CR50","first-page":"60","volume":"3","author":"M Fern\u00e1ndez","year":"2024","unstructured":"Fern\u00e1ndez M, Madri\u00f1an V, Santiago P, Bermudez A. Assessing the feasibility and challenges of CRISPR-Cas9 for treating genetic disorders. J Adv Med Pharm Sci. 2024;3(2):60\u201370.","journal-title":"J Adv Med Pharm Sci"},{"issue":"3","key":"3535_CR51","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.metabol.2014.10.027","volume":"64","author":"M Kalia","year":"2015","unstructured":"Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism. 2015;64(3):S16\u201321.","journal-title":"Metabolism"},{"issue":"1","key":"3535_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","volume":"21","author":"S-W Wang","year":"2022","unstructured":"Wang S-W, Gao C, Zheng Y-M, Yi L, Lu J-C, Huang X-Y, et al. Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer. Mol Cancer. 2022;21(1):57.","journal-title":"Mol Cancer"},{"issue":"11","key":"3535_CR53","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99(11):2191\u2013212.","journal-title":"Am J Hematol"},{"issue":"5","key":"3535_CR54","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.amepre.2014.07.025","volume":"47","author":"MG Beckman","year":"2014","unstructured":"Beckman MG, Hulihan MM, Byams VR, Oakley MA, Reyes N, Trimble S, et al. Public health surveillance of nonmalignant blood disorders. Am J Prev Med. 2014;47(5):664\u20138.","journal-title":"Am J Prev Med"},{"key":"3535_CR55","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1017\/S1463423623000129","volume":"24","author":"GB Black","year":"2023","unstructured":"Black GB, Boswell L, Harris J, Whitaker KL. What causes delays in diagnosing blood cancers? A rapid review of the evidence. Prim Health Care Res Dev. 2023;24:e26.","journal-title":"Prim Health Care Res Dev"},{"key":"3535_CR56","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdl443","volume":"18","author":"D Rodriguez-Abreu","year":"2007","unstructured":"Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol. 2007;18:i3\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"3535_CR57","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1186\/s12885-023-11149-x","volume":"23","author":"L Boswell","year":"2023","unstructured":"Boswell L, Harris J, Ip A, Russell J, Black GB, Whitaker KL. Assessing awareness of blood cancer symptoms and barriers to symptomatic presentation: measure development and results from a population survey in the UK. BMC Cancer. 2023;23(1):633.","journal-title":"BMC Cancer"},{"issue":"4","key":"3535_CR58","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/joim.13697","volume":"294","author":"R Rosenquist","year":"2023","unstructured":"Rosenquist R, Bernard E, Erkers T, Scott DW, Itzykson R, Rousselot P, et al. Novel precision medicine approaches and treatment strategies in hematological malignancies. J Intern Med. 2023;294(4):413\u201336.","journal-title":"J Intern Med"},{"key":"3535_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-38965-8","author":"JT Schiller","year":"2013","unstructured":"Schiller JT, Lowy DR. Virus infection and human cancer: an overview. Viruses Hum Cancer: Basic Sci Clin Prev. 2013. https:\/\/doi.org\/10.1007\/978-3-642-38965-8.","journal-title":"Viruses Hum Cancer: Basic Sci Clin Prev"},{"key":"3535_CR60","doi-asserted-by":"crossref","unstructured":"Sankar V, Villa A. Hematologic diseases. Burket\u2019s Oral Medicine. 2021:627\u2009\u2013\u200964.","DOI":"10.1002\/9781119597797.ch17"},{"key":"3535_CR61","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s11899-019-00542-8","volume":"14","author":"P Torka","year":"2019","unstructured":"Torka P, Barth M, Ferdman R, Hernandez-Ilizaliturri FJ. Mechanisms of resistance to monoclonal antibodies (mAbs) in lymphoid malignancies. Curr Hematol Malig Rep. 2019;14:426\u201338.","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"3535_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"3","key":"3535_CR63","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/nrclinonc.2010.220","volume":"8","author":"SM Hanash","year":"2011","unstructured":"Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers\u2014blood-based strategies to detect and monitor cancer. Nat Reviews Clin Oncol. 2011;8(3):142\u201350.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"4","key":"3535_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123476","volume":"10","author":"MM Kirschner","year":"2015","unstructured":"Kirschner MM, Schemionek M, Schubert C, Chatain N, Sontag S, Isfort S, et al. Dissecting genomic aberrations in myeloproliferative neoplasms by multiplex-PCR and next generation sequencing. PLoS ONE. 2015;10(4):e0123476.","journal-title":"PLoS ONE"},{"issue":"4","key":"3535_CR65","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/annonc\/mdy005","volume":"29","author":"N Guibert","year":"2018","unstructured":"Guibert N, Hu Y, Feeney N, Kuang Y, Plagnol V, Jones G, et al. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Ann Oncol. 2018;29(4):1049\u201355.","journal-title":"Ann Oncol"},{"issue":"1","key":"3535_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-017-0016-z","volume":"1","author":"SH Shin","year":"2017","unstructured":"Shin SH, Bode AM, Dong Z. Precision medicine: the foundation of future cancer therapeutics. NPJ Precis Oncol. 2017;1(1):12.","journal-title":"NPJ Precis Oncol"},{"key":"3535_CR67","doi-asserted-by":"crossref","unstructured":"Stulpinas A, Imbrasait\u0117 A, Krestnikova N, Kalvelyt\u0117 AV. Recent approaches encompassing the phenotypic cell heterogeneity for anticancer drug efficacy. Tumor Progression Metastasis. 2020:147.","DOI":"10.5772\/intechopen.89395"},{"issue":"7","key":"3535_CR68","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","volume":"20","author":"TG Phan","year":"2020","unstructured":"Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20(7):398\u2013411.","journal-title":"Nat Rev Cancer"},{"key":"3535_CR69","doi-asserted-by":"crossref","unstructured":"Thakral D, Gupta R. Acute Myeloid Leukemia: an update. Hematopathology: advances in understanding. 2019:163\u2009\u2013\u200982.","DOI":"10.1007\/978-981-13-7713-6_10"},{"issue":"7","key":"3535_CR70","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/leu.2011.46","volume":"25","author":"A Martelli","year":"2011","unstructured":"Martelli A, Evangelisti C, Chappell W, Abrams SL, B\u00e4secke J, Stivala F, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K\/PTEN\/Akt\/mTOR pathway. Leukemia. 2011;25(7):1064\u201379.","journal-title":"Leukemia"},{"issue":"3\u20134","key":"3535_CR71","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/10428199209067600","volume":"21","author":"M-C L\u00e9glise","year":"1996","unstructured":"L\u00e9glise M-C, Pluchon-rivi\u00e9re E, Calvez GL, Abgrall J-F, Berthou C, Autrand C, et al. Molecular diagnosis and follow up in myeloproliferative syndromes and acute leukemias: correlation between expression of fusion transcripts and disease progression in chronic myeloid leukemia. Leuk Lymphoma. 1996;21(3\u20134):187\u201399.","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"3535_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186623","volume":"21","author":"M Bienz","year":"2020","unstructured":"Bienz M, Ramdani S, Knecht H. Molecular pathogenesis of hodgkin lymphoma: past, present, future. Int J Mol Sci. 2020;21(18):6623.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3535_CR73","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","volume":"35","author":"MA Weniger","year":"2021","unstructured":"Weniger MA, K\u00fcppers R. Molecular biology of Hodgkin lymphoma. Leukemia. 2021;35(4):968\u201381.","journal-title":"Leukemia"},{"key":"3535_CR74","doi-asserted-by":"crossref","unstructured":"Meng X, Min Q, Wang J-Y. B cell lymphoma. B Cells in Immunity and Tolerance. 2020:161\u2009\u2013\u200981.","DOI":"10.1007\/978-981-15-3532-1_12"},{"issue":"1","key":"3535_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4132\/jptm.2021.09.29","volume":"56","author":"M Khanlari","year":"2022","unstructured":"Khanlari M, Chapman JR. Follicular lymphoma: updates for pathologists. J Pathol Transl Med. 2022;56(1):1\u201315.","journal-title":"J Pathol Transl Med"},{"issue":"20","key":"3535_CR76","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.3390\/cancers13205059","volume":"13","author":"M Dillon","year":"2021","unstructured":"Dillon M, Lopez A, Lin E, Sales D, Perets R, Jain P. Progress on ras\/MAPK signaling research and targeting in blood and solid cancers. Cancers. 2021;13(20):5059.","journal-title":"Cancers"},{"issue":"5","key":"3535_CR77","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","volume":"124","author":"MA Krook","year":"2021","unstructured":"Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer. 2021;124(5):880\u201392.","journal-title":"Br J Cancer"},{"issue":"9","key":"3535_CR78","doi-asserted-by":"publisher","first-page":"602","DOI":"10.52586\/4970","volume":"26","author":"M-K Liu","year":"2021","unstructured":"Liu M-K, Sun X-J, Gao X-D, Qian Y, Wang L, Zhao W-L. Methylation alterations and advance of treatment in lymphoma. Front Bioscience-Landmark. 2021;26(9):602\u201313.","journal-title":"Front Bioscience-Landmark"},{"issue":"2","key":"3535_CR79","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2174\/138920210790886853","volume":"11","author":"J Xiang","year":"2010","unstructured":"Xiang J, Wu J. Feud or friend? The role of the miR-17-92 cluster in tumorigenesis. Curr Genomics. 2010;11(2):129\u201335.","journal-title":"Curr Genomics"},{"key":"3535_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1444437","volume":"15","author":"Z Song","year":"2024","unstructured":"Song Z, Tao Y, Liu Y, Li J. Advances in delivery systems for CRISPR\/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles. Front Immunol. 2024;15:1444437.","journal-title":"Front Immunol"},{"issue":"4","key":"3535_CR81","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1399-0004.2011.01809.x","volume":"81","author":"R Kanwal","year":"2012","unstructured":"Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012;81(4):303\u201311.","journal-title":"Clin Genet"},{"issue":"21","key":"3535_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111810","volume":"22","author":"M Halasa","year":"2021","unstructured":"Halasa M, Adamczuk K, Adamczuk G, Afshan S, Stepulak A, Cybulski M, et al. Deacetylation of transcription factors in carcinogenesis. Int J Mol Sci. 2021;22(21):11810.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3535_CR83","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.cr.7310149","volume":"17","author":"P Gallinari","year":"2007","unstructured":"Gallinari P, Marco SD, Jones P, Pallaoro M, Steink\u00fchler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res. 2007;17(3):195\u2013211.","journal-title":"Cell Res"},{"key":"3535_CR84","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.molimm.2019.04.011","volume":"112","author":"S Dahariya","year":"2019","unstructured":"Dahariya S, Paddibhatla I, Kumar S, Raghuwanshi S, Pallepati A, Gutti RK. Long non-coding RNA: classification, biogenesis and functions in blood cells. Mol Immunol. 2019;112:82\u201392.","journal-title":"Mol Immunol"},{"issue":"1","key":"3535_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2014.09.017","volume":"355","author":"S Shukla","year":"2014","unstructured":"Shukla S, Meeran SM, Katiyar SK. Epigenetic regulation by selected dietary phytochemicals in cancer chemoprevention. Cancer Lett. 2014;355(1):9\u201317.","journal-title":"Cancer Lett"},{"issue":"12","key":"3535_CR86","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.3390\/cancers12123657","volume":"12","author":"S Kumar","year":"2020","unstructured":"Kumar S, Gonzalez EA, Rameshwar P, Etchegaray J-P. Non-coding RNAs as mediators of epigenetic changes in malignancies. Cancers (Basel). 2020;12(12):3657.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"3535_CR87","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.gpb.2016.12.005","volume":"15","author":"IM Dykes","year":"2017","unstructured":"Dykes IM, Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genomics Proteomics Bioinformatics. 2017;15(3):177\u201386.","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"3535_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.755053","volume":"12","author":"J Hou","year":"2022","unstructured":"Hou J, He Z, Liu T, Chen D, Wang B, Wen Q, et al. Evolution of molecular targeted cancer therapy: mechanisms of drug resistance and novel opportunities identified by CRISPR-Cas9 screening. Front Oncol. 2022;12:755053.","journal-title":"Front Oncol"},{"issue":"1","key":"3535_CR89","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1186\/s13287-021-02659-1","volume":"12","author":"H Mojtahedi","year":"2021","unstructured":"Mojtahedi H, Yazdanpanah N, Rezaei N. Chronic myeloid leukemia stem cells: targeting therapeutic implications. Stem Cell Res Ther. 2021;12(1):603.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"3535_CR90","first-page":"2183","volume":"42","author":"R Mohanty","year":"2019","unstructured":"Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N. CAR T cell therapy: a new era for cancer treatment. Oncol Rep. 2019;42(6):2183\u201395.","journal-title":"Oncol Rep"},{"issue":"6","key":"3535_CR91","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1158\/2159-8290.CD-13-1014","volume":"4","author":"DA Haber","year":"2014","unstructured":"Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4(6):650\u201361.","journal-title":"Cancer Discov"},{"issue":"10","key":"3535_CR92","doi-asserted-by":"publisher","first-page":"8035","DOI":"10.1007\/s11033-023-08680-2","volume":"50","author":"AM Ali","year":"2023","unstructured":"Ali AM, Salih GF. Molecular and clinical significance of FLT3, NPM1, DNMT3A and TP53 mutations in acute myeloid leukemia patients. Mol Biol Rep. 2023;50(10):8035\u201348.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"3535_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051125","volume":"14","author":"P Persico","year":"2022","unstructured":"Persico P, Lorenzi E, Losurdo A, Dipasquale A, Di Muzio A, Navarria P, et al. Precision oncology in lower-grade gliomas: promises and pitfalls of therapeutic strategies targeting IDH-mutations. Cancers (Basel). 2022;14(5):1125.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"3535_CR94","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/1878-0261.12744","volume":"14","author":"P Blecua","year":"2020","unstructured":"Blecua P, Martinez-Verbo L, Esteller M. The DNA methylation landscape of hematological malignancies: an update. Mol Oncol. 2020;14(8):1616\u201339.","journal-title":"Mol Oncol"},{"issue":"1","key":"3535_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01342-6","volume":"8","author":"A Zhao","year":"2023","unstructured":"Zhao A, Zhou H, Yang J, Li M, Niu T. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Signal Transduct Target Ther. 2023;8(1):71.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"3535_CR96","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","volume":"52","author":"S Raponi","year":"2011","unstructured":"Raponi S, Stefania De Propris M, Intoppa S, Laura Milani M, Vitale A, Elia L, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098\u2013107.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"3535_CR97","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/jcp.51.5.364","volume":"51","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51(5):364\u20139.","journal-title":"J Clin Pathol"},{"issue":"6","key":"3535_CR98","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1038\/bcj.2014.39","volume":"4","author":"A Ehninger","year":"2014","unstructured":"Ehninger A, Kramer M, R\u00f6llig C, Thiede C, Bornh\u00e4user M, Von Bonin M, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4(6):e218\u2013e.","journal-title":"Blood Cancer J"},{"issue":"8","key":"3535_CR99","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ajh.24072","volume":"90","author":"CD DiNardo","year":"2015","unstructured":"DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732\u20136.","journal-title":"Am J Hematol"},{"key":"3535_CR100","doi-asserted-by":"publisher","first-page":"102977","DOI":"10.1016\/j.critrevonc.2020.102977","volume":"151","author":"J Flach","year":"2020","unstructured":"Flach J, Shumilov E, Joncourt R, Porret N, Novak U, Pabst T, et al. Current concepts and future directions for hemato-oncologic diagnostics. Crit Rev Oncol\/Hematol. 2020;151:102977.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"11","key":"3535_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112832","volume":"20","author":"R S\u00e1nchez","year":"2019","unstructured":"S\u00e1nchez R, Ayala R, Mart\u00ednez-L\u00f3pez J. Minimal residual disease monitoring with next-generation sequencing methodologies in hematological malignancies. Int J Mol Sci. 2019;20(11):2832.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3535_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051310","volume":"14","author":"R Colmenares","year":"2022","unstructured":"Colmenares R, \u00c1lvarez N, Barrio S, Mart\u00ednez-L\u00f3pez J, Ayala R. The minimal residual disease using liquid biopsies in hematological malignancies. Cancers. 2022;14(5):1310.","journal-title":"Cancers"},{"issue":"30","key":"3535_CR103","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1038\/onc.2013.346","volume":"33","author":"Y He","year":"2014","unstructured":"He Y, Jiang X, Chen J. The role of miR-150 in normal and malignant hematopoiesis. Oncogene. 2014;33(30):3887\u201393.","journal-title":"Oncogene"},{"key":"3535_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101019","volume":"58","author":"W Walter","year":"2023","unstructured":"Walter W, Pohlkamp C, Meggendorfer M, Nadarajah N, Kern W, Haferlach C, et al. Artificial intelligence in hematological diagnostics: game changer or gadget? Blood Rev. 2023;58:101019.","journal-title":"Blood Rev"},{"issue":"1","key":"3535_CR105","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12935-021-01981-1","volume":"21","author":"MJ Iqbal","year":"2021","unstructured":"Iqbal MJ, Javed Z, Sadia H, Qureshi IA, Irshad A, Ahmed R, et al. Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. Cancer Cell Int. 2021;21(1):270.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"3535_CR106","first-page":"25","volume":"3","author":"M Payandeh","year":"2009","unstructured":"Payandeh M, Aeinfar M, Aeinfar V, Hayati M. A new method for diagnosis and predicting blood disorder and cancer using artificial intelligence (artificial neural networks). Int J Hematology-Oncology Stem Cell Res. 2009;3(4):25\u201333.","journal-title":"Int J Hematology-Oncology Stem Cell Res"},{"issue":"21","key":"3535_CR107","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.3390\/cancers15215297","volume":"15","author":"W Wiese","year":"2023","unstructured":"Wiese W, Barczuk J, Racinska O, Siwecka N, Rozpedek-Kaminska W, Slupianek A, et al. PI3K\/Akt\/mTOR signaling pathway in blood malignancies\u2014new therapeutic possibilities. Cancers. 2023;15(21):5297.","journal-title":"Cancers"},{"issue":"8","key":"3535_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082907","volume":"21","author":"I Nepstad","year":"2020","unstructured":"Nepstad I, Hatfield KJ, Gr\u00f8nnings\u00e6ter IS, Reikvam H. The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci. 2020;21(8):2907.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3535_CR109","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3324\/haematol.2009.013797","volume":"95","author":"S Park","year":"2009","unstructured":"Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, et al. Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2009;95(5):819.","journal-title":"Haematologica"},{"issue":"9","key":"3535_CR110","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.2174\/187152009789377772","volume":"9","author":"K Kawauchi","year":"2009","unstructured":"Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K, Yamada O. Regulation and importance of the PI3K\/Akt\/mTOR signaling pathway in hematologic malignancies. Anti-Cancer Agents Med Chem. 2009;9(9):1024\u201338.","journal-title":"Anti-Cancer Agents Med Chem"},{"issue":"1","key":"3535_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01442-3","volume":"8","author":"M You","year":"2023","unstructured":"You M, Xie Z, Zhang N, Zhang Y, Xiao D, Liu S, et al. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):196.","journal-title":"Signal Transduct Target Ther"},{"issue":"31","key":"3535_CR112","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.2174\/1568026621666210902120754","volume":"21","author":"DD Singh","year":"2021","unstructured":"Singh DD, Verma R, Tripathi SK, Sahu R, Trivedi P, Yadav DK. Breast cancer transcriptional regulatory network reprogramming by using the CRISPR\/Cas9 system: an oncogenetics perspective. Curr Top Med Chem. 2021;21(31):2800\u201313.","journal-title":"Curr Top Med Chem"},{"issue":"13","key":"3535_CR113","doi-asserted-by":"publisher","first-page":"e125832","DOI":"10.1172\/jci.insight.125832","volume":"4","author":"S Hemmati","year":"2019","unstructured":"Hemmati S, Sinclair T, Tong M, Bartholdy B, Okabe RO, Ames K, et al. PI3K alpha and delta promote hematopoietic stem cell activation. JCI Insight. 2019;4(13):e125832.","journal-title":"JCI Insight"},{"issue":"6","key":"3535_CR114","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3892\/ol.2024.14700","volume":"28","author":"S Wang","year":"2024","unstructured":"Wang S, Liu C, Yang C, Jin Y, Cui Q, Wang D, et al. PI3K\/AKT\/mTOR and PD\u20131\/CTLA\u20134\/CD28 pathways as key targets of cancer immunotherapy. Oncol Lett. 2024;28(6):567.","journal-title":"Oncol Lett"},{"issue":"8","key":"3535_CR115","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463\u201382.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3535_CR116","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12943-023-01925-5","volume":"23","author":"M Chehelgerdi","year":"2024","unstructured":"Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024;23(1):9.","journal-title":"Mol Cancer"},{"issue":"21","key":"3535_CR117","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/onc.2012.347","volume":"32","author":"W Vainchenker","year":"2013","unstructured":"Vainchenker W, Constantinescu SN. JAK\/STAT signaling in hematological malignancies. Oncogene. 2013;32(21):2601\u201313.","journal-title":"Oncogene"},{"issue":"1","key":"3535_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01934-w","volume":"9","author":"Y Lv","year":"2024","unstructured":"Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, et al. The JAK-STAT pathway: from structural biology to cytokine engineering. Signal Transduct Target Ther. 2024;9(1):221.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"3535_CR119","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1600-0609.2004.00242.x","volume":"72","author":"M Ba\u015bkiewicz-Masiuk","year":"2004","unstructured":"Ba\u015bkiewicz-Masiuk M, Machali\u0144ski B. The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AML cells. Eur J Haematol. 2004;72(6):420\u20139.","journal-title":"Eur J Haematol"},{"issue":"8","key":"3535_CR120","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1242\/jcs.00963","volume":"117","author":"JS Rawlings","year":"2004","unstructured":"Rawlings JS, Rosler KM, Harrison DA. The JAK\/STAT signaling pathway. J Cell Sci. 2004;117(8):1281\u20133.","journal-title":"J Cell Sci"},{"issue":"12","key":"3535_CR121","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","volume":"27","author":"R Morris","year":"2018","unstructured":"Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK\/STAT pathway. Protein Sci. 2018;27(12):1984\u20132009.","journal-title":"Protein Sci"},{"key":"3535_CR122","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.clml.2014.06.014","volume":"14","author":"F Pasquier","year":"2014","unstructured":"Pasquier F, Cabagnols X, Secardin L, Plo I, Vainchenker W. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy. Clin Lymphoma Myeloma Leuk. 2014;14:S23\u201335.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"3535_CR123","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.exphem.2016.07.010","volume":"44","author":"J Shi","year":"2016","unstructured":"Shi J, Yuan B, Hu W, Lodish H. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways. Exp Hematol. 2016;44(11):1044\u201358. e5.","journal-title":"Exp Hematol"},{"issue":"10","key":"3535_CR124","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/leu.2008.236","volume":"22","author":"J Kota","year":"2008","unstructured":"Kota J, Caceres N, Constantinescu SN. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia. 2008;22(10):1828\u201340.","journal-title":"Leukemia"},{"issue":"2","key":"3535_CR125","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/biom12020291","volume":"12","author":"DG Torres","year":"2022","unstructured":"Torres DG, Paes J, da Costa AG, Malheiro A, Silva GV, Mour\u00e3o LPS, et al. JAK2 variant signaling: genetic, hematologic and immune implication in chronic myeloproliferative neoplasms. Biomolecules. 2022;12(2):291.","journal-title":"Biomolecules"},{"issue":"1","key":"3535_CR126","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","volume":"1","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1(1):97\u2013105.","journal-title":"JAMA Oncol"},{"issue":"1","key":"3535_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02778-6","volume":"22","author":"M Al-Haideri","year":"2022","unstructured":"Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT, et al. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int. 2022;22(1):365.","journal-title":"Cancer Cell Int"},{"key":"3535_CR128","doi-asserted-by":"publisher","first-page":"821344","DOI":"10.3389\/fphar.2022.821344","volume":"13","author":"B Rah","year":"2022","unstructured":"Rah B, Rather RA, Bhat GR, Baba AB, Mushtaq I, Farooq M, et al. JAK\/STAT signaling: molecular targets, therapeutic opportunities, and limitations of targeted inhibitions in solid malignancies. Front Pharmacol. 2022;13:821344.","journal-title":"Front Pharmacol"},{"issue":"12","key":"3535_CR129","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.3390\/cancers11122002","volume":"11","author":"KL Owen","year":"2019","unstructured":"Owen KL, Brockwell NK, Parker BS. Jak-stat signaling: a double-edged sword of immune regulation and cancer progression. Cancers. 2019;11(12):2002.","journal-title":"Cancers"},{"issue":"1","key":"3535_CR130","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cells10010016","volume":"10","author":"L Gragnani","year":"2020","unstructured":"Gragnani L, Lorini S, Marri S, Zignego AL. Role of Notch receptors in hematologic malignancies. Cells. 2020;10(1):16.","journal-title":"Cells"},{"key":"3535_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-11-502","volume":"11","author":"J Pancewicz","year":"2011","unstructured":"Pancewicz J, Nicot C. Current views on the role of Notch signaling and the pathogenesis of human leukemia. BMC Cancer. 2011;11:1\u20137.","journal-title":"BMC Cancer"},{"key":"3535_CR132","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12079-015-0271-0","volume":"9","author":"S Suresh","year":"2015","unstructured":"Suresh S, Irvine AE. The NOTCH signaling pathway in normal and malignant blood cell production. J Cell Commun Signal. 2015;9:5\u201313.","journal-title":"J Cell Commun Signal"},{"key":"3535_CR133","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/bs.pmbts.2017.11.002","volume":"153","author":"S Grainger","year":"2018","unstructured":"Grainger S, Traver D, Willert K. Wnt signaling in hematological malignancies. Prog Mol Biol Transl Sci. 2018;153:321\u201341.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"5704","key":"3535_CR134","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1126\/science.1104742","volume":"306","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090\u20133.","journal-title":"Science"},{"issue":"2","key":"3535_CR135","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.blre.2010.09.004","volume":"25","author":"M Paganin","year":"2011","unstructured":"Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 2011;25(2):83\u201390.","journal-title":"Blood Rev"},{"key":"3535_CR136","doi-asserted-by":"crossref","unstructured":"Ranganath R, Nagashree NR. Role of programmed cell death in development. 2001.","DOI":"10.1016\/S0074-7696(01)02005-8"},{"issue":"7","key":"3535_CR137","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0968-0004(96)10031-1","volume":"21","author":"M Rechsteiner","year":"1996","unstructured":"Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci. 1996;21(7):267\u201371.","journal-title":"Trends Biochem Sci"},{"issue":"8","key":"3535_CR138","first-page":"830","volume":"133","author":"V Close","year":"2019","unstructured":"Close V, Close W, Kugler SJ, Reichenzeller M, Yosifov DY, Bloehdorn J, et al. FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. Blood. J Am Soc Hematol. 2019;133(8):830\u20139.","journal-title":"J Am Soc Hematol"},{"key":"3535_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00550","volume":"8","author":"F Arruga","year":"2018","unstructured":"Arruga F, Vaisitti T, Deaglio S. The NOTCH pathway and its mutations in mature B cell malignancies. Front Oncol. 2018;8:550.","journal-title":"Front Oncol"},{"issue":"1","key":"3535_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00934-y","volume":"7","author":"B Zhou","year":"2022","unstructured":"Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022;7(1):95.","journal-title":"Signal Transduct Target Ther"},{"key":"3535_CR141","doi-asserted-by":"crossref","unstructured":"Giaimo BD, Gagliani EK, Kovall RA, Borggrefe T. Transcription factor RBPJ as a molecular switch in regulating the Notch response. Notch Signal Embryol Cancer: Notch Signal Cancer. 2021:9\u201330.","DOI":"10.1007\/978-3-030-55031-8_2"},{"key":"3535_CR142","unstructured":"Oliveira DV. Unraveling the role of NOTCH3 dysfunction in disease and for therapy development: a focus on cadasil. Karolinska Institutet (Sweden); 2021."},{"issue":"25","key":"3535_CR143","doi-asserted-by":"publisher","first-page":"10549","DOI":"10.1074\/jbc.M117.791707","volume":"292","author":"N Tabaja","year":"2017","unstructured":"Tabaja N, Yuan Z, Oswald F, Kovall RA. Structure-function analysis of RBP-J-interacting and tubulin-associated (RITA) reveals regions critical for repression of Notch target genes. J Biol Chem. 2017;292(25):10549\u201363.","journal-title":"J Biol Chem"},{"issue":"3","key":"3535_CR144","first-page":"1997","volume":"19","author":"Y-J Guo","year":"2020","unstructured":"Guo Y-J, Pan W-W, Liu S-B, Shen Z-F, Xu Y, Hu. L-L. ERK\/MAPK signalling pathway and tumorigenesis. Experimental Therapeutic Med. 2020;19(3):1997\u20132007.","journal-title":"Experimental Therapeutic Med"},{"issue":"6","key":"3535_CR145","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1681\/ASN.V561288","volume":"5","author":"B Margolis","year":"1994","unstructured":"Margolis B, Skolnik EY. Activation of Ras by receptor tyrosine kinases. J Am Soc Nephrol. 1994;5(6):1288\u201399.","journal-title":"J Am Soc Nephrol"},{"key":"3535_CR146","doi-asserted-by":"crossref","unstructured":"Schlessinger J, Bar-Sagi D. Activation of Ras and other signaling pathways by receptor tyrosine kinases. Cold spring harbor symposia on quantitative biology. Cold Spring Harbor Laboratory Press; 1994. pp. 173\u20139.","DOI":"10.1101\/SQB.1994.059.01.021"},{"issue":"1","key":"3535_CR147","first-page":"25","volume":"1653","author":"KE Mercer","year":"2003","unstructured":"Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochimica et Biophysica Acta (BBA). 2003;1653(1):25\u201340.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"7","key":"3535_CR148","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","volume":"14","author":"M Holderfield","year":"2014","unstructured":"Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):455\u201367.","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"3535_CR149","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/cncr.28864","volume":"120","author":"M Burotto","year":"2014","unstructured":"Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer. 2014;120(22):3446\u201356.","journal-title":"Cancer"},{"issue":"1","key":"3535_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01574-x","volume":"15","author":"Y Hu","year":"2023","unstructured":"Hu Y, Shen F, Yang X, Han T, Long Z, Wen J, et al. Single-cell sequencing technology applied to epigenetics for the study of tumor heterogeneity. Clin Epigenetics. 2023;15(1):161.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"3535_CR151","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/s41467-020-18875-x","volume":"11","author":"M Martinez-Lage","year":"2020","unstructured":"Martinez-Lage M, Torres-Ruiz R, Puig-Serra P, Moreno-Gaona P, Martin MC, Moya FJ, et al. In vivo CRISPR\/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. Nat Commun. 2020;11(1):5060.","journal-title":"Nat Commun"},{"issue":"16","key":"3535_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168996","volume":"22","author":"T Haslauer","year":"2021","unstructured":"Haslauer T, Greil R, Zaborsky N, Geisberger R. Car T-cell therapy in hematological malignancies. Int J Mol Sci. 2021;22(16):8996.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3535_CR153","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3390\/cancers11101618","volume":"11","author":"C Braicu","year":"2019","unstructured":"Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers. 2019;11(10):1618.","journal-title":"Cancers"},{"issue":"11","key":"3535_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119666","volume":"24","author":"J-I Park","year":"2023","unstructured":"Park J-I. MAPK-ERK, pathway. Int J Mol Sci. 2023;24(11):9666.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3535_CR155","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1080\/10428194.2017.1370548","volume":"59","author":"A Shukla","year":"2018","unstructured":"Shukla A, Shukla V, Joshi SS. Regulation of MAPK signaling and implications in chronic lymphocytic leukemia. Leuk Lymphoma. 2018;59(7):1565\u201373.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"3535_CR156","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3390\/cancers14030666","volume":"14","author":"E Vendramini","year":"2022","unstructured":"Vendramini E, Bomben R, Pozzo F, Bittolo T, Tissino E, Gattei V, et al. KRAS and RAS-MAPK pathway deregulation in mature B cell lymphoproliferative disorders. Cancers. 2022;14(3):666.","journal-title":"Cancers"},{"issue":"3","key":"3535_CR157","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.drup.2007.03.003","volume":"10","author":"G Tortora","year":"2007","unstructured":"Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, et al. Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat. 2007;10(3):81\u2013100.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"3535_CR158","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S1556-0864(15)31506-9","volume":"1","author":"JR Molina","year":"2006","unstructured":"Molina JR, Adjei AA. The ras\/raf\/mapk pathway. J Thorac Oncol. 2006;1(1):7\u20139.","journal-title":"J Thorac Oncol"},{"key":"3535_CR159","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S93545","author":"KA Tran","year":"2015","unstructured":"Tran KA, Cheng MY, Mitra A, Ogawa H, Shi VY, Olney LP, et al. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Development Therapy. 2015. https:\/\/doi.org\/10.2147\/DDDT.S93545.","journal-title":"Drug Des Development Therapy"},{"key":"3535_CR160","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/B978-0-444-56330-9.00012-7","volume-title":"The role of catalysis for the sustainable production of bio-fuels and bio-chemicals","author":"R Rauch","year":"2013","unstructured":"Rauch R, Kiennemann A, Sauciuc A. Fischer-Tropsch synthesis to biofuels (BtL process). In: The role of catalysis for the sustainable production of bio-fuels and bio-chemicals. Elsevier; 2013. p. 397\u2013443."},{"issue":"2","key":"3535_CR161","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/med.21993","volume":"44","author":"X Lu","year":"2024","unstructured":"Lu X, Jin J, Wu Y, Liu X, Liang X, Lin J, et al. Progress in RAS-targeted therapeutic strategies: from small molecule inhibitors to proteolysis targeting chimeras. Med Res Rev. 2024;44(2):812\u201332.","journal-title":"Med Res Rev"},{"issue":"1","key":"3535_CR162","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/genes5010051","volume":"5","author":"N Chami","year":"2014","unstructured":"Chami N, Lettre G. Lessons and implications from genome-wide association studies (GWAS) findings of blood cell phenotypes. Genes. 2014;5(1):51\u201364.","journal-title":"Genes"},{"issue":"14","key":"3535_CR163","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143583","volume":"15","author":"RJ Marrero","year":"2023","unstructured":"Marrero RJ, Lamba JK. Current landscape of genome-wide association studies in acute myeloid leukemia: a review. Cancers. 2023;15(14):3583.","journal-title":"Cancers"},{"issue":"11","key":"3535_CR164","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nrc.2017.82","volume":"17","author":"A Sud","year":"2017","unstructured":"Sud A, Kinnersley B, Houlston RS. Genome-wide association studies of cancer: current insights and future perspectives. Nat Rev Cancer. 2017;17(11):692\u2013704.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3535_CR165","first-page":"33","volume":"20","author":"S Timmermans","year":"2016","unstructured":"Timmermans S, Shostak S. Gene worlds. Health (San Francisco). 2016;20(1):33\u201348.","journal-title":"Health (San Francisco)"},{"issue":"1","key":"3535_CR166","first-page":"1","volume":"95","author":"JN Hellwege","year":"2017","unstructured":"Hellwege JN, Keaton JM, Giri A, Gao X, Velez Edwards DR, Edwards TL. Population stratification in genetic association studies. Curr Protocols Hum Genet. 2017;95(1):1. 1\u20131. 3.","journal-title":"Curr Protocols Hum Genet"},{"issue":"3","key":"3535_CR167","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/gepi.21879","volume":"39","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Pan W. Principal component regression and linear mixed model in association analysis of structured samples: competitors or complements? Genet Epidemiol. 2015;39(3):149\u201355.","journal-title":"Genet Epidemiol"},{"issue":"6","key":"3535_CR168","doi-asserted-by":"publisher","DOI":"10.1002\/cem.3232","volume":"34","author":"M Martin","year":"2020","unstructured":"Martin M, Govaerts B. LiMM\u2010PCA: combining ASCA\u2009+\u2009and linear mixed models to analyse high\u2010dimensional designed data. J Chemom. 2020;34(6):e3232.","journal-title":"J Chemom"},{"issue":"11","key":"3535_CR169","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/ng.3105","volume":"46","author":"JR Cerhan","year":"2014","unstructured":"Cerhan JR, Berndt SI, Vijai J, Ghesqui\u00e8res H, McKay J, Wang SS, et al. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet. 2014;46(11):1233\u20138.","journal-title":"Nat Genet"},{"issue":"1","key":"3535_CR170","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ctm2.28","volume":"10","author":"Z Ahmed","year":"2020","unstructured":"Ahmed Z, Zeeshan S, Mendhe D, Dong X. Human gene and disease associations for clinical-genomics and precision medicine research. Clin Transl Med. 2020;10(1):297\u2013318.","journal-title":"Clin Transl Med"},{"issue":"38","key":"3535_CR171","doi-asserted-by":"publisher","first-page":"25355","DOI":"10.18632\/oncotarget.25256","volume":"9","author":"R Palmirotta","year":"2018","unstructured":"Palmirotta R, Carella C, Silvestris E, Cives M, Stucci SL, Tucci M, et al. SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. Oncotarget. 2018;9(38):25355.","journal-title":"Oncotarget"},{"issue":"9","key":"3535_CR172","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S1470-2045(09)70359-6","volume":"11","author":"MR Speicher","year":"2010","unstructured":"Speicher MR, Geigl JB, Tomlinson IP. Effect of genome-wide association studies, direct-to-consumer genetic testing, and high-speed sequencing technologies on predictive genetic counselling for cancer risk. Lancet Oncol. 2010;11(9):890\u20138.","journal-title":"Lancet Oncol"},{"issue":"sup6","key":"3535_CR173","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2144\/jun0210","volume":"32","author":"RS Schifreen","year":"2002","unstructured":"Schifreen RS, Storts DR, Buller AM. The challenge of using SNPs in the understanding and treatment of disease. Biotechniques. 2002;32(sup6):S14-21.","journal-title":"Biotechniques"},{"key":"3535_CR174","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.oraloncology.2018.09.001","volume":"86","author":"C Andreassen","year":"2018","unstructured":"Andreassen C, Eriksen J, Jensen K, Hansen C, S\u00f8rensen B, Lassen P, et al. IMRT\u2013biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. Oral Oncol. 2018;86:91\u20139.","journal-title":"Oral Oncol"},{"issue":"5","key":"3535_CR175","first-page":"327","volume":"61","author":"JN Weitzel","year":"2011","unstructured":"Weitzel JN, Blazer KR, MacDonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin. 2011;61(5):327\u201359.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3535_CR176","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microarrays5010001","volume":"5","author":"J Song","year":"2015","unstructured":"Song J, Shao H. SNP array in hematopoietic neoplasms: a review. Microarrays. 2015;5(1):1.","journal-title":"Microarrays"},{"issue":"1","key":"3535_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43141-7","volume":"13","author":"M Dratwa","year":"2023","unstructured":"Dratwa M, \u0141acina P, Butrym A, Porzuczek D, Mazur G, Bogunia-Kubik K. Telomere length and h TERT genetic variants as potential prognostic markers in multiple myeloma. Sci Rep. 2023;13(1):15792.","journal-title":"Sci Rep"},{"issue":"6","key":"3535_CR178","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","volume":"99","author":"H Avet-Loiseau","year":"2002","unstructured":"Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp M-J, Harousseau J-L, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99(6):2185\u201391.","journal-title":"Blood"},{"issue":"4","key":"3535_CR179","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3109\/10428194.2010.551155","volume":"52","author":"P Economopoulou","year":"2011","unstructured":"Economopoulou P, Pappa V, Papageorgiou S, Dervenoulas J, Economopoulos T. Abnormalities of DNA repair mechanisms in common hematological malignancies. Leuk Lymphoma. 2011;52(4):567\u201382.","journal-title":"Leuk Lymphoma"},{"key":"3535_CR180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-017-1057-4","volume":"34","author":"A Dylawerska","year":"2017","unstructured":"Dylawerska A, Barczak W, Wegner A, Golusinski W, Suchorska WM. Association of DNA repair genes polymorphisms and mutations with increased risk of head and neck cancer: a review. Med Oncol. 2017;34:1\u20138.","journal-title":"Med Oncol"},{"issue":"13","key":"3535_CR181","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2217\/fon-2015-0035","volume":"12","author":"M Verma","year":"2016","unstructured":"Verma M. Genome-wide association studies and epigenome-wide association studies go together in cancer control. Future Oncol. 2016;12(13):1645\u201364.","journal-title":"Future Oncol"},{"key":"3535_CR182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12864-018-4963-8","volume":"19","author":"K Blighe","year":"2018","unstructured":"Blighe K, DeDionisio L, Christie K, Chawes B, Shareef S, Kakouli-Duarte T, et al. Gene editing in the context of an increasingly complex genome. BMC Genomics. 2018;19:1\u201320.","journal-title":"BMC Genomics"},{"issue":"9","key":"3535_CR183","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/jnci\/djac101","volume":"114","author":"X Zhao","year":"2022","unstructured":"Zhao X, Qian M, Goodings C, Zhang Y, Yang W, Wang P, et al. Molecular mechanisms of ARID5B-mediated genetic susceptibility to acute lymphoblastic leukemia. J Natl Cancer Inst. 2022;114(9):1287\u201395.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3535_CR184","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/nyas.12362","volume":"1310","author":"H Greim","year":"2014","unstructured":"Greim H, Kaden DA, Larson RA, Palermo CM, Rice JM, Ross D, et al. The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann N Y Acad Sci. 2014;1310(1):7\u201331.","journal-title":"Ann N Y Acad Sci"},{"key":"3535_CR185","first-page":"609","volume":"26","author":"L-I Hsu","year":"2015","unstructured":"Hsu L-I, Chokkalingam AP, Briggs FB, Walsh K, Crouse V, Fu C, et al. Association of genetic variation in IKZF1, ARID5B, and CEBPE and surrogates for early-life infections with the risk of acute lymphoblastic leukemia in Hispanic children. Cancer Causes Control. 2015;26:609\u201319.","journal-title":"Cancer Causes Control"},{"issue":"9","key":"3535_CR186","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092167","volume":"13","author":"E Leveille","year":"2021","unstructured":"Leveille E, Johnson NA. Genetic events inhibiting apoptosis in diffuse large B cell lymphoma. Cancers (Basel). 2021;13(9):2167.","journal-title":"Cancers (Basel)"},{"key":"3535_CR187","unstructured":"Hanker A, Rajkumar K, He Z, Ohneda O, Nguyen H-NT, Kawahara M et al. Frontiers frontiers in oncology ORIGINAL RESEARCH published: 07 June 2022. Women in Breast Cancer: 2022, II. 2023:6"},{"issue":"9","key":"3535_CR188","doi-asserted-by":"publisher","first-page":"dev182667","DOI":"10.1242\/dev.182667","volume":"148","author":"E Akinci","year":"2021","unstructured":"Akinci E, Hamilton MC, Khowpinitchai B, Sherwood RI. Using CRISPR to understand and manipulate gene regulation. Development. 2021;148(9):dev182667.","journal-title":"Development"},{"issue":"2","key":"3535_CR189","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/FPC.0000000000000453","volume":"32","author":"T Moriyama","year":"2022","unstructured":"Moriyama T, Yang W, Smith C, Pui C-H, Evans WE, Relling MV, et al. Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2022;32(2):60\u20136.","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"3535_CR190","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","volume":"22","author":"GI Ellis","year":"2021","unstructured":"Ellis GI, Sheppard NC, Riley JL. Genetic engineering of T cells for immunotherapy. Nat Rev Genet. 2021;22(7):427\u201347.","journal-title":"Nat Rev Genet"},{"key":"3535_CR191","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1385\/IR:33:2:113","volume":"33","author":"RL Ferris","year":"2005","unstructured":"Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class i defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res. 2005;33:113\u201333.","journal-title":"Immunol Res"},{"key":"3535_CR192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-016-0297-1","volume":"40","author":"A Chavez-Gonzalez","year":"2017","unstructured":"Chavez-Gonzalez A, Bakhshinejad B, Pakravan K, Guzman ML, Babashah S. Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer. Cell Oncol. 2017;40:1\u201320.","journal-title":"Cell Oncol"},{"issue":"8","key":"3535_CR193","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrg3523","volume":"14","author":"TA Manolio","year":"2013","unstructured":"Manolio TA. Bringing genome-wide association findings into clinical use. Nat Rev Genet. 2013;14(8):549\u201358.","journal-title":"Nat Rev Genet"},{"issue":"11","key":"3535_CR194","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.041988","volume":"12","author":"S Rahman","year":"2019","unstructured":"Rahman S, Mansour MR. The role of noncoding mutations in blood cancers. Dis Model Mech. 2019;12(11):dmm041988.","journal-title":"Dis Model Mech"},{"key":"3535_CR195","doi-asserted-by":"publisher","DOI":"10.1007\/s43032-024-01666-w","author":"P Pourmasoumi","year":"2024","unstructured":"Pourmasoumi P, Moradi A, Bayat M. BRCA1\/2 mutations and breast\/ovarian cancer risk: a new insights review. Reproductive Sci. 2024. https:\/\/doi.org\/10.1007\/s43032-024-01666-w.","journal-title":"Reproductive Sci"},{"issue":"8","key":"3535_CR196","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001077","volume":"146","author":"JW O\u2019Sullivan","year":"2022","unstructured":"O\u2019Sullivan JW, Raghavan S, Marquez-Luna C, Luzum JA, Damrauer SM, Ashley EA, et al. Polygenic risk scores for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2022;146(8):e93-118.","journal-title":"Circulation"},{"issue":"12","key":"3535_CR197","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","volume":"46","author":"S Iodice","year":"2010","unstructured":"Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis. Eur J Cancer. 2010;46(12):2275\u201384.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3535_CR198","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.mpmed.2023.10.002","volume":"52","author":"M Pirmohamed","year":"2024","unstructured":"Pirmohamed M. Pharmacogenetics for the prescriber. Medicine. 2024;52(1):11\u20134.","journal-title":"Medicine"},{"issue":"8","key":"3535_CR199","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41431-024-01572-4","volume":"32","author":"LE Manson","year":"2024","unstructured":"Manson LE, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk A-M, Houwink EJ, et al. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. Eur J Hum Genet. 2024;32(8):903\u201311.","journal-title":"Eur J Hum Genet"},{"issue":"24","key":"3535_CR200","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413302","volume":"22","author":"R Cacabelos","year":"2021","unstructured":"Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic factors and pharmacogenomics in adverse drug reactions. Int J Mol Sci. 2021;22(24):13302.","journal-title":"Int J Mol Sci"},{"key":"3535_CR201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01431-6","volume":"20","author":"H Zhang","year":"2021","unstructured":"Zhang H, Qin C, An C, Zheng X, Wen S, Chen W, et al. Application of the CRISPR\/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer. 2021;20:1\u201322.","journal-title":"Mol Cancer"},{"key":"3535_CR202","first-page":"65","volume-title":"Clustered regularly interspaced short palindromic repeats\/CRISPR-associated (CRISPR\/Cas) systems: Discovery, structure, classification, and general mechanism. CRISPR\/Cas-Mediated Genome Editing in Plants","author":"S Ganger","year":"2023","unstructured":"Ganger S, Harale G, Majumdar P. Clustered regularly interspaced short palindromic repeats\/CRISPR-associated (CRISPR\/Cas) systems: Discovery, structure, classification, and general mechanism. CRISPR\/Cas-Mediated Genome Editing in Plants. Apple Academic; 2023. p. 65\u201397."},{"issue":"6213","key":"3535_CR203","doi-asserted-by":"publisher","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.","journal-title":"Science"},{"issue":"1","key":"3535_CR204","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1731","volume":"14","author":"LF Hu","year":"2023","unstructured":"Hu LF, Li YX, Wang JZ, Zhao YT, Wang Y. Controlling CRISPR-Cas9 by guide RNA engineering. WIREs RNA. 2023;14(1):e1731.","journal-title":"WIREs RNA"},{"issue":"1","key":"3535_CR205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0304-3835(02)00692-4","volume":"193","author":"FV Rassool","year":"2003","unstructured":"Rassool FV. DNA double strand breaks (DSB) and non-homologous end joining (NHEJ) pathways in human leukemia. Cancer Lett. 2003;193(1):1\u20139.","journal-title":"Cancer Lett"},{"key":"3535_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102344","author":"H Liao","year":"2024","unstructured":"Liao H, Wu J, VanDusen NJ, Li Y, Zheng Y. CRISPR-Cas9-mediated homology-directed repair for precise gene editing. Mol Ther. 2024. https:\/\/doi.org\/10.1016\/j.omtn.2024.102344.","journal-title":"Mol Ther"},{"key":"3535_CR207","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2018.00691","volume":"9","author":"M Liu","year":"2019","unstructured":"Liu M, Rehman S, Tang X, Gu K, Fan Q, Chen D, et al. Methodologies for improving HDR efficiency. Front Genet. 2019;9:691.","journal-title":"Front Genet"},{"issue":"7","key":"3535_CR208","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3390\/genes15070863","volume":"15","author":"R Kansal","year":"2024","unstructured":"Kansal R. The CRISPR-Cas system and clinical applications of CRISPR-based gene editing in hematology with a focus on inherited germline predisposition to hematologic malignancies. Genes. 2024;15(7):863.","journal-title":"Genes"},{"issue":"3","key":"3535_CR209","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/03630269.2010.486335","volume":"34","author":"GJ Kontoghiorghes","year":"2010","unstructured":"Kontoghiorghes GJ, Spyrou A, Kolnagou A. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and Non regulatory mechanisms of increased iron absorption. Hemoglobin. 2010;34(3):251\u201364.","journal-title":"Hemoglobin"},{"key":"3535_CR210","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-016-0108-0","volume":"35","author":"Z-J Kang","year":"2016","unstructured":"Kang Z-J, Liu Y-F, Xu L-Z, Long Z-J, Huang D, Yang Y, et al. The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 2016;35:1\u201315.","journal-title":"Chin J Cancer"},{"issue":"2","key":"3535_CR211","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/biology10020118","volume":"10","author":"E Vuelta","year":"2021","unstructured":"Vuelta E, Garc\u00eda-Tu\u00f1\u00f3n I, Hern\u00e1ndez-Carabias P, M\u00e9ndez L, S\u00e1nchez-Mart\u00edn M. Future approaches for treating chronic myeloid leukemia: CRISPR therapy. Biology. 2021;10(2):118.","journal-title":"Biology"},{"issue":"21","key":"3535_CR212","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/sj.onc.1205322","volume":"21","author":"U Krug","year":"2002","unstructured":"Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene. 2002;21(21):3475\u201395.","journal-title":"Oncogene"},{"issue":"3","key":"3535_CR213","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/humu.10190","volume":"21","author":"S Peller","year":"2003","unstructured":"Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat. 2003;21(3):277\u201384.","journal-title":"Hum Mutat"},{"issue":"1","key":"3535_CR214","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0300-9084(01)01356-6","volume":"84","author":"D Guimaraes","year":"2002","unstructured":"Guimaraes D, Hainaut P. TP53: a key gene in human cancer. Biochimie. 2002;84(1):83\u201393.","journal-title":"Biochimie"},{"key":"3535_CR215","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.3389\/fimmu.2020.02062","volume":"11","author":"M Azangou-Khyavy","year":"2020","unstructured":"Azangou-Khyavy M, Ghasemi M, Khanali J, Boroomand-Saboor M, Jamalkhah M, Soleimani M, et al. CRISPR\/Cas: from tumor gene editing to T cell-based immunotherapy of cancer. Front Immunol. 2020;11:2062.","journal-title":"Front Immunol"},{"key":"3535_CR216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-019-1086-5","volume":"20","author":"SM Miri","year":"2020","unstructured":"Miri SM, Tafsiri E, Cho WCS, Ghaemi A. CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy. Cancer Cell Int. 2020;20:1\u201317.","journal-title":"Cancer Cell Int"},{"key":"3535_CR217","doi-asserted-by":"publisher","first-page":"834002","DOI":"10.3389\/fonc.2022.834002","volume":"12","author":"E Elmas","year":"2022","unstructured":"Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, et al. CRISPR gene editing of human primary NK and T cells for cancer immunotherapy. Front Oncol. 2022;12:834002.","journal-title":"Front Oncol"},{"issue":"01","key":"3535_CR218","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0044-1785234","volume":"11","author":"ND Kolanu","year":"2024","unstructured":"Kolanu ND. CRISPR\u2013Cas9 gene editing: curing genetic diseases by inherited epigenetic modifications. Glob Med Genet. 2024;11(01):113\u201322.","journal-title":"Glob Med Genet"},{"key":"3535_CR219","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2024.148865","author":"S Zanganeh","year":"2024","unstructured":"Zanganeh S, Zahedi AM, Bardsiri MS, Bazi A, Bastanifard M, Shool S, et al. Recent advances and applications of the CRISPR-Cas system in the gene therapy of blood disorders. Gene. 2024. https:\/\/doi.org\/10.1016\/j.gene.2024.148865.","journal-title":"Gene"},{"key":"3535_CR220","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.3389\/fpls.2018.01874","volume":"9","author":"SZ Agapito-Tenfen","year":"2018","unstructured":"Agapito-Tenfen SZ, Okoli AS, Bernstein MJ, Wikmark O-G, Myhr AI. Revisiting risk governance of GM plants: the need to consider new and emerging gene-editing techniques. Front Plant Sci. 2018;9:1874.","journal-title":"Front Plant Sci"},{"issue":"3","key":"3535_CR221","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/mt.2016.10","volume":"24","author":"ML Maeder","year":"2016","unstructured":"Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther. 2016;24(3):430\u201346.","journal-title":"Mol Ther"},{"issue":"11","key":"3535_CR222","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1042\/BCJ20170793","volume":"475","author":"A Eid","year":"2018","unstructured":"Eid A, Alshareef S, Mahfouz MM. Crispr base editors: genome editing without double-stranded breaks. Biochem J. 2018;475(11):1955\u201364.","journal-title":"Biochem J"},{"issue":"2","key":"3535_CR223","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1021\/acschembio.7b00710","volume":"13","author":"AC Komor","year":"2018","unstructured":"Komor AC, Badran AH, Liu DR. Editing the genome without double-stranded DNA breaks. ACS Chem Biol. 2018;13(2):383\u20138.","journal-title":"ACS Chem Biol"},{"issue":"16","key":"3535_CR224","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.3390\/cancers15164137","volume":"15","author":"A Chergui","year":"2023","unstructured":"Chergui A, Reagan JL. Immunotherapy in acute leukemias: past success paves the way for future progress. Cancers. 2023;15(16):4137.","journal-title":"Cancers"},{"issue":"1","key":"3535_CR225","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01521-5","volume":"8","author":"L Tang","year":"2023","unstructured":"Tang L, Huang Z, Mei H, Hu Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Ther. 2023;8(1):306.","journal-title":"Signal Transduct Target Ther"},{"key":"3535_CR226","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1182\/blood-2023-184345","volume":"142","author":"G Ahmed","year":"2023","unstructured":"Ahmed G, Alsouqi A, Szabo A, Rojek AE, Riedell PA, Awan FT, et al. Chimeric antigen receptor T-cell (CAR-T) therapy in secondary central nervous system large B-cell lymphoma (SCNSL): a multicenter retrospective analysis. Blood. 2023;142:3088.","journal-title":"Blood"},{"issue":"4","key":"3535_CR227","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005.","journal-title":"Leukemia"},{"issue":"4","key":"3535_CR228","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473\u201388.","journal-title":"Cancer Cell"},{"issue":"3","key":"3535_CR229","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Reviews Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"2","key":"3535_CR230","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"4","key":"3535_CR231","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3535_CR232","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","volume":"224","author":"BT Fife","year":"2008","unstructured":"Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA\u20104 and PD\u20101 pathways. Immunol Rev. 2008;224(1):166\u201382.","journal-title":"Immunol Rev"},{"issue":"1","key":"3535_CR233","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021;40(1):184.","journal-title":"J Exp Clin Cancer Res"},{"issue":"66","key":"3535_CR234","doi-asserted-by":"publisher","first-page":"110693","DOI":"10.18632\/oncotarget.22690","volume":"8","author":"J Bai","year":"2017","unstructured":"Bai J, Gao Z, Li X, Dong L, Han W, Nie J. Regulation of PD-1\/PD-L1 pathway and resistance to PD-1\/PD-L1 blockade. Oncotarget. 2017;8(66):110693.","journal-title":"Oncotarget"},{"key":"3535_CR235","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","volume":"15","author":"W Xie","year":"2020","unstructured":"Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. PD-1\/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas. Curr Hematol Malig Rep. 2020;15:372\u201381.","journal-title":"Curr Hematol Malig Rep"},{"issue":"26","key":"3535_CR236","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","volume":"1","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Armand P, Wright KT, Rodig SJ. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1(26):2643\u201354.","journal-title":"Blood Adv"},{"issue":"1","key":"3535_CR237","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98\u2013106.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"3535_CR238","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41422-018-0012-z","volume":"28","author":"X Du","year":"2018","unstructured":"Du X, Liu M, Su J, Zhang P, Tang F, Ye P, et al. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. Cell Res. 2018;28(4):433\u201347.","journal-title":"Cell Res"},{"issue":"12","key":"3535_CR239","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.21037\/atm-20-6833","volume":"9","author":"H Hatic","year":"2021","unstructured":"Hatic H, Sampat D, Goyal G. Immune checkpoint inhibitors in lymphoma: challenges and opportunities. Ann Transl Med. 2021;9(12):1037.","journal-title":"Ann Transl Med"},{"issue":"8","key":"3535_CR240","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/bjc.2013.117","volume":"108","author":"S Quezada","year":"2013","unstructured":"Quezada S, Peggs K. Exploiting. CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer. 2013;108(8):1560\u20135.","journal-title":"Br J Cancer"},{"issue":"S11","key":"3535_CR241","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/cncr.30444","volume":"123","author":"EH Byrne","year":"2017","unstructured":"Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer. 2017;123(S11):2143\u201353.","journal-title":"Cancer"},{"issue":"9","key":"3535_CR242","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1002\/cncr.32659","volume":"126","author":"SM Bair","year":"2020","unstructured":"Bair SM, Brandstadter JD, Ayers EC, Stadtmauer EA. Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer. 2020;126(9):1837\u201355.","journal-title":"Cancer"},{"issue":"1","key":"3535_CR243","first-page":"6084012","volume":"2019","author":"H Nishida","year":"2019","unstructured":"Nishida H, Yamada T. Monoclonal antibody therapies in multiple myeloma: a challenge to develop novel targets. J Oncol. 2019;2019(1):6084012.","journal-title":"J Oncol"},{"issue":"47","key":"3535_CR244","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359\u201368.","journal-title":"Oncogene"},{"key":"3535_CR245","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-394802-1.00001-7","volume-title":"Antibody Fc","author":"VRG Rom\u00e1n","year":"2014","unstructured":"Rom\u00e1n VRG, Murray JC, Weiner LM. Antibody-dependent cellular cytotoxicity (ADCC). In: Antibody Fc. Elsevier; 2014. p. 1\u201327. https:\/\/doi.org\/10.1016\/B978-0-12-394802-1.00001-7."},{"issue":"1","key":"3535_CR246","doi-asserted-by":"publisher","first-page":"749","DOI":"10.4049\/jimmunol.0900632","volume":"183","author":"AW Pawluczkowycz","year":"2009","unstructured":"Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009;183(1):749\u201358.","journal-title":"J Immunol"},{"issue":"10","key":"3535_CR247","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s00277-004-0917-0","volume":"83","author":"M Stanglmaier","year":"2004","unstructured":"Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol. 2004;83(10):634\u201345.","journal-title":"Ann Hematol"},{"issue":"1","key":"3535_CR248","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010167","volume":"9","author":"I Saltarella","year":"2020","unstructured":"Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, et al. Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells. 2020;9(1):167.","journal-title":"Cells"},{"key":"3535_CR249","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0305-7372(03)00077-X","volume":"29","author":"WS Dalton","year":"2003","unstructured":"Dalton WS. The tumor microenvironment: focus on myeloma. Cancer Treat Rev. 2003;29:11\u20139.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"3535_CR250","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020217","volume":"13","author":"A Garcia-Ortiz","year":"2021","unstructured":"Garcia-Ortiz A, Rodriguez-Garcia Y, Encinas J, Maroto-Martin E, Castellano E, Teixid\u00f3 J, et al. The role of tumor microenvironment in multiple myeloma development and progression. Cancers (Basel). 2021;13(2):217.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"3535_CR251","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"M-E Goebeler","year":"2020","unstructured":"Goebeler M-E, Bargou RC. T cell-engaging therapies\u2014BiTEs and beyond. Nat Rev Clin Oncol. 2020;17(7):418\u201334.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3535_CR252","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290\u20136.","journal-title":"Immunol Cell Biol"},{"issue":"2","key":"3535_CR253","doi-asserted-by":"publisher","first-page":"e001202","DOI":"10.1136\/jitc-2020-001202","volume":"8","author":"JL Gardell","year":"2020","unstructured":"Gardell JL, Matsumoto LR, Chinn H, DeGolier KR, Kreuser SA, Prieskorn B, et al. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma. J Immunother Cancer. 2020;8(2):e001202.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"3535_CR254","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.4049\/jimmunol.161.6.3176","volume":"161","author":"AL Tutt","year":"1998","unstructured":"Tutt AL, French RR, Illidge TM, Honeychurch J, McBride HM, Penfold CA, et al. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J Immunol. 1998;161(6):3176\u201385.","journal-title":"J Immunol"},{"issue":"8","key":"3535_CR255","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell\u2013cancer cycle: advances and new challenges in NK cell\u2013based immunotherapies. Nat Immunol. 2020;21(8):835\u201347.","journal-title":"Nat Immunol"},{"issue":"1","key":"3535_CR256","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14712598.2020.1688298","volume":"20","author":"AG Pockley","year":"2020","unstructured":"Pockley AG, Vaupel P, Multhoff G. NK cell-based therapeutics for lung cancer. Expert Opin Biol Ther. 2020;20(1):23\u201333.","journal-title":"Expert Opin Biol Ther"},{"issue":"24","key":"3535_CR257","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245836","volume":"15","author":"Y Du","year":"2023","unstructured":"Du Y, Pollok KE, Shen J. Unlocking glioblastoma secrets: natural killer cell therapy against cancer stem cells. Cancers. 2023;15(24):5836.","journal-title":"Cancers"},{"key":"3535_CR258","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S99807","author":"S Serrat\u00ec","year":"2016","unstructured":"Serrat\u00ec S, De Summa S, Pilato B, Petriella D, Lacalamita R, Tommasi S, et al. Next-generation sequencing: advances and applications in cancer diagnosis. Onco Targets Ther. 2016. https:\/\/doi.org\/10.2147\/OTT.S99807.","journal-title":"Onco Targets Ther"},{"issue":"10","key":"3535_CR259","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/jjco\/hyv122","volume":"45","author":"T Shibata","year":"2015","unstructured":"Shibata T. Current and future molecular profiling of cancer by next-generation sequencing. Jpn J Clin Oncol. 2015;45(10):895\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"3535_CR260","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltad013","volume":"3","author":"WM Zhu","year":"2023","unstructured":"Zhu WM, Middleton MR. Combination therapies for the optimisation of bispecific T-cell engagers in cancer treatment. Immunotherapy Advances. 2023;3(1):ltad013.","journal-title":"Immunotherapy Advances"},{"issue":"8","key":"3535_CR261","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","volume":"8","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, et al. Association of high tumor mutation burden in non\u2013small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022;8(8):1160\u20138.","journal-title":"JAMA Oncol"},{"key":"3535_CR262","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3389\/fimmu.2020.00490","volume":"11","author":"L Gibellini","year":"2020","unstructured":"Gibellini L, De Biasi S, Porta C, Lo Tartaro D, Depenni R, Pellacani G, et al. Single-cell approaches to profile the response to immune checkpoint inhibitors. Front Immunol. 2020;11:490.","journal-title":"Front Immunol"},{"issue":"12","key":"3535_CR263","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"3535_CR264","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000515305","volume":"10","author":"C-L Hsu","year":"2021","unstructured":"Hsu C-L, Ou D-L, Bai L-Y, Chen C-W, Lin L, Huang S-F, et al. Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma. Liver Cancer. 2021;10(4):346\u201359.","journal-title":"Liver Cancer"},{"key":"3535_CR265","doi-asserted-by":"crossref","unstructured":"Jain K. Biotechnology-based Drug Discovery. Molecular Biology and Biotechnology. 2009:307.","DOI":"10.1039\/9781849730211-00307"},{"key":"3535_CR266","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2022.100190","author":"S Namba","year":"2022","unstructured":"Namba S, Konuma T, Wu K-H, Zhou W, Okada Y. A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. Cell Genom. 2022. https:\/\/doi.org\/10.1016\/j.xgen.2022.100190.","journal-title":"Cell Genom"},{"key":"3535_CR267","volume-title":"The principles behind targeted therapy for cancer treatment","author":"A-B Wabel","year":"2019","unstructured":"Wabel A-B, Khajah M. The principles behind targeted therapy for cancer treatment. IntechOpen: Tumor progression and metastasis.; 2019."},{"key":"3535_CR268","doi-asserted-by":"crossref","unstructured":"Manley PW, Stiefl NJ. Progress in the discovery of BCR-ABL kinase inhibitors for the treatment of leukemia. Cancer II. 2018:1\u201337.","DOI":"10.1007\/7355_2017_5"},{"key":"3535_CR269","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005004.pub3","author":"T Filippini","year":"2020","unstructured":"Filippini T, Malavolti M, Borrelli F, Izzo AA, Fairweather-Tait SJ, Horneber M, et al. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Reviews. 2020. https:\/\/doi.org\/10.1002\/14651858.CD005004.pub3.","journal-title":"Cochrane Database Syst Reviews"},{"issue":"19\u201320","key":"3535_CR270","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.drudis.2013.06.001","volume":"18","author":"GK Lambert","year":"2013","unstructured":"Lambert GK, Duhme-Klair A-K, Morgan T, Ramjee MK. The background, discovery and clinical development of BCR-ABL inhibitors. Drug Discov Today. 2013;18(19\u201320):992\u20131000.","journal-title":"Drug Discov Today"},{"issue":"6","key":"3535_CR271","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","volume":"25","author":"JA Burger","year":"2019","unstructured":"Burger JA. Bruton tyrosine kinase inhibitors: present and future. Cancer J. 2019;25(6):386\u201393.","journal-title":"Cancer J"},{"issue":"1","key":"3535_CR272","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.","journal-title":"Mol Cancer"},{"key":"3535_CR273","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.931462","volume":"12","author":"X Zhuang","year":"2022","unstructured":"Zhuang X, Pei HZ, Li T, Huang J, Guo Y, Zhao Y, et al. The molecular mechanisms of resistance to IDH inhibitors in acute myeloid leukemia. Front Oncol. 2022;12:931462.","journal-title":"Front Oncol"},{"key":"3535_CR274","first-page":"165","volume-title":"Biochemical, epigenetic, and metabolic approaches to target IDH mutations in acute myeloid leukemia","author":"AT Fathi","year":"2015","unstructured":"Fathi AT, Wander SA, Faramand R, Emadi A. Biochemical, epigenetic, and metabolic approaches to target IDH mutations in acute myeloid leukemia. Seminars in hematology: Elsevier; 2015. pp. 165\u201371."},{"issue":"8","key":"3535_CR275","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12032-022-01711-1","volume":"39","author":"S Quazi","year":"2022","unstructured":"Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Med Oncol. 2022;39(8):120.","journal-title":"Med Oncol"},{"issue":"1","key":"3535_CR276","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00994-0","volume":"7","author":"Y You","year":"2022","unstructured":"You Y, Lai X, Pan Y, Zheng H, Vera J, Liu S, et al. Artificial intelligence in cancer target identification and drug discovery. Signal Transduct Target Ther. 2022;7(1):156.","journal-title":"Signal Transduct Target Ther"},{"key":"3535_CR277","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s11030-021-10217-3","volume":"25","author":"R Gupta","year":"2021","unstructured":"Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Diversity. 2021;25:1315\u201360.","journal-title":"Mol Diversity"},{"issue":"3","key":"3535_CR278","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jbiotec.2005.03.022","volume":"119","author":"B Ganter","year":"2005","unstructured":"Ganter B, Tugendreich S, Pearson CI, Ayanoglu E, Baumhueter S, Bostian KA, et al. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol. 2005;119(3):219\u201344.","journal-title":"J Biotechnol"},{"key":"3535_CR279","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-018-0282-6","volume":"20","author":"L Pu","year":"2019","unstructured":"Pu L, Naderi M, Liu T, Wu H-C, Mukhopadhyay S, Brylinski M. E toxpred: A machinE learning-based approach to estimatE thE toxicity of drug candidates. BMC Pharmacol Toxicol. 2019;20:1\u201315.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"3535_CR280","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/1389450117666160606104208","volume":"18","author":"G Misso","year":"2017","unstructured":"Misso G, Rachele Zarone M, Grimaldi A, Di Teresa M, Lombardi A, Kawasaki H, et al. Non coding rnas: a new avenue for the self-tailoring of blood cancer treatment. Curr Drug Targets. 2017;18(1):35\u201355.","journal-title":"Curr Drug Targets"},{"issue":"13","key":"3535_CR281","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137156","volume":"22","author":"L Anelli","year":"2021","unstructured":"Anelli L, Zagaria A, Specchia G, Musto P, Albano F. Dysregulation of miRNA in leukemia: exploiting miRNA expression profiles as biomarkers. Int J Mol Sci. 2021;22(13):7156.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3535_CR282","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2174\/1566524011313040009","volume":"13","author":"M Schmitt","year":"2013","unstructured":"Schmitt M, Margue C, Behrmann I, Kreis S. Mirna-29: a MicroRNA family with tumor-suppressing and immune-modulating properties. Curr Mol Med. 2013;13(4):572\u201385.","journal-title":"Curr Mol Med"},{"key":"3535_CR283","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/529312","volume":"2013","author":"E Hatzimichael","year":"2013","unstructured":"Hatzimichael E, Crook T. Cancer epigenetics: new therapies and new challenges. J Drug Deliv. 2013;2013:2013(1):529312.","journal-title":"J Drug Deliv"},{"issue":"7","key":"3535_CR284","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","volume":"1","author":"RA Juergens","year":"2011","unstructured":"Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non\u2013small cell lung cancer. Cancer Discov. 2011;1(7):598\u2013607.","journal-title":"Cancer Discov"},{"key":"3535_CR285","first-page":"172","volume-title":"Epigenetic therapy in acute myeloid leukemia: current and future directions","author":"TK Kim","year":"2015","unstructured":"Kim TK, Gore SD, Zeidan AM. Epigenetic therapy in acute myeloid leukemia: current and future directions. Seminars in hematology: Elsevier; 2015. pp. 172\u201383."},{"issue":"5","key":"3535_CR286","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/apm.12906","volume":"127","author":"K Dimopoulos","year":"2019","unstructured":"Dimopoulos K, Gr\u00f8nb\u00e6k K. Epigenetic therapy in hematological cancers. APMIS. 2019;127(5):316\u201328.","journal-title":"APMIS"},{"issue":"5","key":"3535_CR287","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/PPO.0b013e3181bd0445","volume":"15","author":"DS Tan","year":"2009","unstructured":"Tan DS, Thomas GV, Garrett MD, Banerji U, De Bono JS, Kaye SB, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J. 2009;15(5):406\u201320.","journal-title":"Cancer J"},{"key":"3535_CR288","doi-asserted-by":"publisher","DOI":"10.4018\/979-8-3693-6597-7.ch006","volume-title":"Introduction to genomic-driven drug discovery. genomics-driven drug discovery through pharmacogenomics","author":"AA Parikesit","year":"2025","unstructured":"Parikesit AA. Introduction to genomic-driven drug discovery. genomics-driven drug discovery through pharmacogenomics. IGI Global Scientific Publishing; 2025. https:\/\/doi.org\/10.4018\/979-8-3693-6597-7.ch006."},{"issue":"08","key":"3535_CR289","first-page":"54","volume":"18","author":"N Jyothi","year":"2023","unstructured":"Jyothi N. AI-enabled genomic biomarkers: the future of pharmaceutical industry and personalized medicine. Seybold Rep J. 2023;18(08):54\u201372.","journal-title":"Seybold Rep J"},{"key":"3535_CR290","volume":"229","author":"S Taefehshokr","year":"2022","unstructured":"Taefehshokr S, Parhizkar A, Hayati S, Mousapour M, Mahmoudpour A, Eleid L, et al. Cancer immunotherapy: challenges and limitations. Pathology. 2022;229:153723.","journal-title":"Pathology"},{"issue":"16","key":"3535_CR291","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163972","volume":"14","author":"C Peterson","year":"2022","unstructured":"Peterson C, Denlinger N, Yang Y. Recent advances and challenges in cancer immunotherapy. Cancers. 2022;14(16):3972.","journal-title":"Cancers"},{"issue":"1","key":"3535_CR292","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11033-023-09096-8","volume":"51","author":"A Zafar","year":"2024","unstructured":"Zafar A, Khan MJ, Abu J, Naeem A. Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. Mol Biol Rep. 2024;51(1):219.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"3535_CR293","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/cancers13040806","volume":"13","author":"N El-Sayes","year":"2021","unstructured":"El-Sayes N, Vito A, Mossman K. Tumor heterogeneity: a great barrier in the age of cancer immunotherapy. Cancers. 2021;13(4):806.","journal-title":"Cancers"},{"issue":"1","key":"3535_CR294","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00277-y","volume":"11","author":"Q Jia","year":"2022","unstructured":"Jia Q, Wang A, Yuan Y, Zhu B, Long H. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp Hematol Oncol. 2022;11(1):24.","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"3535_CR295","doi-asserted-by":"publisher","first-page":"e0263672","DOI":"10.1371\/journal.pone.0263672","volume":"17","author":"DA Howell","year":"2022","unstructured":"Howell DA, McCaughan D, Smith AG, Patmore R, Roman E. Incurable but treatable: understanding, uncertainty and impact in chronic blood cancers\u2014a qualitative study from the UK\u2019s haematological malignancy research network. PLoS ONE. 2022;17(2):e0263672.","journal-title":"PLoS ONE"},{"issue":"4","key":"3535_CR296","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/molecules27041310","volume":"27","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Lin W, Zhu L. Targeted drug delivery for the treatment of blood cancers. Molecules. 2022;27(4):1310.","journal-title":"Molecules"},{"issue":"7","key":"3535_CR297","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers16071440","volume":"16","author":"S Casagrande","year":"2024","unstructured":"Casagrande S, Sopetto GB, Bertalot G, Bortolotti R, Racanelli V, Caffo O, et al. Immune-related adverse events due to cancer immunotherapy: immune mechanisms and clinical manifestations. Cancers (Basel). 2024;16(7):1440.","journal-title":"Cancers (Basel)"},{"key":"3535_CR298","doi-asserted-by":"publisher","first-page":"1197364","DOI":"10.3389\/fimmu.2023.1197364","volume":"14","author":"B Ibis","year":"2023","unstructured":"Ibis B, Aliazis K, Cao C, Yenyuwadee S, Boussiotis VA. Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases. Front Immunol. 2023;14:1197364.","journal-title":"Front Immunol"},{"issue":"12","key":"3535_CR299","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27123798","volume":"27","author":"MM Rahman","year":"2022","unstructured":"Rahman MM, Behl T, Islam MR, Alam MN, Islam MM, Albarrati A, et al. Emerging management approach for the adverse events of immunotherapy of cancer. Molecules. 2022;27(12):3798.","journal-title":"Molecules"},{"issue":"3","key":"3535_CR300","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1042\/ETLS20180146","volume":"3","author":"SA Gkazi","year":"2019","unstructured":"Gkazi SA. Quantifying CRISPR off-target effects. Emerg Top Life Sci. 2019;3(3):327\u201334.","journal-title":"Emerg Top Life Sci"},{"key":"3535_CR301","doi-asserted-by":"publisher","first-page":"1143157","DOI":"10.3389\/fbioe.2023.1143157","volume":"11","author":"C Guo","year":"2023","unstructured":"Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR\/Cas9 gene editing. Front Bioeng Biotechnol. 2023;11:1143157.","journal-title":"Front Bioeng Biotechnol"},{"issue":"2","key":"3535_CR302","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12033-022-00550-9","volume":"65","author":"S Maity","year":"2023","unstructured":"Maity S, Mukherjee R, Banerjee S. Recent advances and therapeutic strategies using CRISPR genome editing technique for the treatment of cancer. Mol Biotechnol. 2023;65(2):206\u201326.","journal-title":"Mol Biotechnol"},{"issue":"1","key":"3535_CR303","first-page":"37","volume":"1","author":"S Rehman","year":"2024","unstructured":"Rehman S. Ethical implications of genetic engineering: balancing innovation and responsibility. Front Biotechnol Genet. 2024;1(1):37\u201355.","journal-title":"Front Biotechnol Genet"},{"issue":"2\u20133","key":"3535_CR304","doi-asserted-by":"publisher","first-page":"50","DOI":"10.14740\/wjon1345","volume":"12","author":"AA Adeniji","year":"2021","unstructured":"Adeniji AA, Dulal S, Martin MG. Personalized medicine in oncology in the developing world: barriers and concepts to improve status quo. World J Oncol. 2021;12(2\u20133):50.","journal-title":"World J Oncol"},{"key":"3535_CR305","volume-title":"Access to personalised oncology in Europe","author":"J Gill","year":"2020","unstructured":"Gill J, Fontrier A-M, Miracolo A, Kanavos P. Access to personalised oncology in Europe. London School of Economics; 2020."},{"issue":"1","key":"3535_CR306","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1145\/2767007","volume":"48","author":"M Naveed","year":"2015","unstructured":"Naveed M, Ayday E, Clayton EW, Fellay J, Gunter CA, Hubaux J-P, et al. Privacy in the genomic era. ACM Comput Surv. 2015;48(1):1\u201344.","journal-title":"ACM Comput Surv"},{"key":"3535_CR307","doi-asserted-by":"crossref","unstructured":"Tyagi AK. Privacy preservation of genomic and medical data. Wiley; 2023.","DOI":"10.1002\/9781394213726"},{"issue":"4","key":"3535_CR308","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/japp.12249","volume":"34","author":"C Gyngell","year":"2017","unstructured":"Gyngell C, Douglas T, Savulescu J. The ethics of germline gene editing. J Appl Philos. 2017;34(4):498\u2013513.","journal-title":"J Appl Philos"},{"key":"3535_CR309","unstructured":"Green RM. Babies by design: the ethics of genetic choice. Yale University Press; 2007."},{"issue":"1","key":"3535_CR310","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.30574\/ijsra.2023.8.1.0189","volume":"8","author":"H Ali","year":"2023","unstructured":"Ali H. Artificial intelligence in multi-omics data integration: advancing precision medicine, biomarker discovery and genomic-driven disease interventions. Int J Sci Res Arch. 2023;8(1):1012\u201330.","journal-title":"Int J Sci Res Arch"},{"issue":"11","key":"3535_CR311","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115751","volume":"22","author":"F Pettini","year":"2021","unstructured":"Pettini F, Visibelli A, Cicaloni V, Iovinelli D, Spiga O. Multi-omics model applied to cancer genetics. Int J Mol Sci. 2021;22(11):5751.","journal-title":"Int J Mol Sci"},{"key":"3535_CR312","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.csbj.2021.01.009","volume":"19","author":"O Menyh\u00e1rt","year":"2021","unstructured":"Menyh\u00e1rt O, Gy\u0151rffy B. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J. 2021;19:949\u201360.","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"3535_CR313","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab454","volume":"23","author":"M Kang","year":"2022","unstructured":"Kang M, Ko E, Mersha TB. A roadmap for multi-omics data integration using deep learning. Brief Bioinform. 2022;23(1):bbab454.","journal-title":"Brief Bioinform"},{"key":"3535_CR314","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.824451","volume":"13","author":"B Arjmand","year":"2022","unstructured":"Arjmand B, Hamidpour SK, Tayanloo-Beik A, Goodarzi P, Aghayan HR, Adibi H, et al. Machine learning: a new prospect in multi-omics data analysis of cancer. Front Genet. 2022;13:824451.","journal-title":"Front Genet"},{"key":"3535_CR315","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103798","author":"Z Cai","year":"2022","unstructured":"Cai Z, Poulos RC, Liu J, Zhong Q. Machine learning for multi-omics data integration in cancer. iScience. 2022. https:\/\/doi.org\/10.1016\/j.isci.2022.103798.","journal-title":"iScience"},{"key":"3535_CR316","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.119686","author":"Z Xu","year":"2024","unstructured":"Xu Z, Li W, Dong X, Chen Y, Zhang D, Wang J, et al. Precision medicine in colorectal cancer: leveraging multi-omics, spatial omics, and artificial intelligence. Clin Chim Acta. 2024. https:\/\/doi.org\/10.1016\/j.cca.2024.119686.","journal-title":"Clin Chim Acta"},{"issue":"7","key":"3535_CR317","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3390\/biomedicines12071496","volume":"12","author":"AE Mohr","year":"2024","unstructured":"Mohr AE, Ortega-Santos CP, Whisner CM, Klein-Seetharaman J, Jasbi P. Navigating challenges and opportunities in multi-omics integration for personalized healthcare. Biomedicines. 2024;12(7):1496.","journal-title":"Biomedicines"},{"key":"3535_CR318","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00423","volume":"10","author":"G de Anda-J\u00e1uregui","year":"2020","unstructured":"de Anda-J\u00e1uregui G, Hern\u00e1ndez-Lemus E. Computational oncology in the multi-omics era: state of the art. Front Oncol. 2020;10:423.","journal-title":"Front Oncol"},{"key":"3535_CR319","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1510792","volume":"11","author":"F Li","year":"2025","unstructured":"Li F, Wang S, Gao Z, Qing M, Pan S, Liu Y, et al. Harnessing artificial intelligence in sepsis care: advances in early detection, personalized treatment, and real-time monitoring. Front Med. 2025;11:1510792.","journal-title":"Front Med"},{"issue":"12","key":"3535_CR320","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.62347\/MWNZ5609","volume":"14","author":"C Zhang","year":"2024","unstructured":"Zhang C, Li N, Zhang P, Jiang Z, Cheng Y, Li H, et al. Advancing precision and personalized breast cancer treatment through multi-omics technologies. Am J Cancer Res. 2024;14(12):5614.","journal-title":"Am J Cancer Res"},{"issue":"8","key":"3535_CR321","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/cncr.24975","volume":"116","author":"MJ McKeage","year":"2010","unstructured":"McKeage MJ, Baguley BC. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer. 2010;116(8):1859\u201371.","journal-title":"Cancer"},{"issue":"10","key":"3535_CR322","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102526","volume":"14","author":"W Wiese","year":"2022","unstructured":"Wiese W, Siwecka N, Wawrzynkiewicz A, Rozp\u0119dek-Kami\u0144ska W, Kucharska E, Majsterek I. IRE1\u03b1 inhibitors as a promising therapeutic strategy in blood malignancies. Cancers. 2022;14(10):2526.","journal-title":"Cancers"},{"issue":"3","key":"3535_CR323","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/cancers17030382","volume":"17","author":"M El-Tanani","year":"2025","unstructured":"El-Tanani M, Rabbani SA, Satyam SM, Rangraze IR, Wali AF, El-Tanani Y, et al. Deciphering the role of cancer stem cells: drivers of tumor evolution, therapeutic resistance, and precision medicine strategies. Cancers (Basel). 2025;17(3):382.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"3535_CR324","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.55248\/gengpi.5.1024.2905","volume":"5","author":"AF Segun","year":"2024","unstructured":"Segun AF. Advances in personalized medical therapeutics: leveraging genomics for targeted treatments. Int J Res Publ Rev. 2024;5(10):2921\u201333.","journal-title":"Int J Res Publ Rev"},{"issue":"8","key":"3535_CR325","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41417-021-00418-1","volume":"29","author":"M Sheykhhasan","year":"2022","unstructured":"Sheykhhasan M, Manoochehri H, Dama P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Ther. 2022;29(8):1080\u201396.","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"3535_CR326","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/leu.2014.124","volume":"28","author":"A Im","year":"2014","unstructured":"Im A, Sehgal A, Carroll M, Smith B, Tefferi A, Johnson D, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014;28(9):1774\u201383.","journal-title":"Leukemia"},{"issue":"6","key":"3535_CR327","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer J. 2021;11(6):107.","journal-title":"Blood Cancer J"},{"issue":"3","key":"3535_CR328","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrc.2016.3","volume":"16","author":"M Greaves","year":"2016","unstructured":"Greaves M. Leukaemia\u2019firsts\u2019 in cancer research and treatment. Nat Rev Cancer. 2016;16(3):163\u201372.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3535_CR329","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3535_CR330","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1021\/acsnano.7b05108","volume":"12","author":"CM Hartshorn","year":"2018","unstructured":"Hartshorn CM, Bradbury MS, Lanza GM, Nel AE, Rao J, Wang AZ, et al. Nanotechnology strategies to advance outcomes in clinical cancer care. ACS Nano. 2018;12(1):24\u201343.","journal-title":"ACS Nano"},{"key":"3535_CR331","doi-asserted-by":"crossref","unstructured":"Bibbins-Domingo K, Helman A. Improving representation in clinical trials and research. 2022.","DOI":"10.17226\/26479"},{"issue":"3","key":"3535_CR332","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrg.2017.89","volume":"19","author":"LA Hindorff","year":"2018","unstructured":"Hindorff LA, Bonham VL, Brody LC, Ginoza ME, Hutter CM, Manolio TA, et al. Prioritizing diversity in human genomics research. Nat Rev Genet. 2018;19(3):175\u201385.","journal-title":"Nat Rev Genet"},{"issue":"6","key":"3535_CR333","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"3535_CR334","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100640","volume":"40","author":"V Bachanova","year":"2020","unstructured":"Bachanova V, Perales M-A, Abramson JS. Modern management of relapsed and refractory aggressive B-cell lymphoma: a perspective on the current treatment landscape and patient selection for CAR T-cell therapy. Blood Rev. 2020;40:100640.","journal-title":"Blood Rev"},{"issue":"8","key":"3535_CR335","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-020-0892-7","volume":"55","author":"M Mohty","year":"2020","unstructured":"Mohty M, Dulery R, Gauthier J, Malard F, Brissot E, Aljurf M, et al. CAR T-cell therapy for the management of refractory\/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant. 2020;55(8):1525\u201332.","journal-title":"Bone Marrow Transplant"},{"key":"3535_CR336","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.109137","volume":"182","author":"A Boretti","year":"2024","unstructured":"Boretti A. The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy. Comput Biol Med. 2024;182:109137.","journal-title":"Comput Biol Med"},{"issue":"10","key":"3535_CR337","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","volume":"27","author":"Y Hu","year":"2021","unstructured":"Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L, et al. CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2021;27(10):2764\u201372.","journal-title":"Clin Cancer Res"},{"key":"3535_CR338","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.694526","volume":"11","author":"A Bhingarkar","year":"2021","unstructured":"Bhingarkar A, Vangapandu HV, Rathod S, Hoshitsuki K, Fernandez CA. Amino acid metabolic vulnerabilities in acute and chronic myeloid leukemias. Front Oncol. 2021;11:694526.","journal-title":"Front Oncol"},{"key":"3535_CR339","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.674720","volume":"11","author":"L Fultang","year":"2021","unstructured":"Fultang L, Gneo L, De Santo C, Mussai FJ. Targeting amino acid metabolic vulnerabilities in myeloid malignancies. Front Oncol. 2021;11:674720.","journal-title":"Front Oncol"},{"issue":"5","key":"3535_CR340","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","volume":"34","author":"CL Jones","year":"2018","unstructured":"Jones CL, Stevens BM, D\u2019Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34(5):724\u201340. e4.","journal-title":"Cancer Cell"},{"issue":"7","key":"3535_CR341","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/imcb.12557","volume":"100","author":"P Liao","year":"2022","unstructured":"Liao P, Chang N, Xu B, Qiu Y, Wang S, Zhou L, et al. Amino acid metabolism: challenges and opportunities for the therapeutic treatment of leukemia and lymphoma. Immunol Cell Biol. 2022;100(7):507\u201328.","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"3535_CR342","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13045-017-0509-9","volume":"10","author":"MKL Fung","year":"2017","unstructured":"Fung MKL, Chan GC-F. Drug-induced amino acid deprivation as strategy for cancer therapy. J Hematol Oncol. 2017;10(1):144.","journal-title":"J Hematol Oncol"},{"issue":"13","key":"3535_CR343","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood.2019001034","volume":"134","author":"Y Tabe","year":"2019","unstructured":"Tabe Y, Lorenzi PL, Konopleva M. Amino acid metabolism in hematologic malignancies and the era of targeted therapy. Blood. 2019;134(13):1014\u201323.","journal-title":"Blood"},{"issue":"8","key":"3535_CR344","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3390\/cells8080805","volume":"8","author":"J Kreitz","year":"2019","unstructured":"Kreitz J, Sch\u00f6nfeld C, Seibert M, Stolp V, Alshamleh I, Oellerich T, et al. Metabolic plasticity of acute myeloid leukemia. Cells. 2019;8(8):805.","journal-title":"Cells"},{"key":"3535_CR345","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-017-1354-4","volume":"18","author":"E Zuo","year":"2017","unstructured":"Zuo E, Huo X, Yao X, Hu X, Sun Y, Yin J, et al. CRISPR\/Cas9-mediated targeted chromosome elimination. Genome Biol. 2017;18:1\u201318.","journal-title":"Genome Biol"},{"issue":"13","key":"3535_CR346","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-18-3223","volume":"25","author":"MA Gregory","year":"2019","unstructured":"Gregory MA, Nemkov T, Park HJ, Zaberezhnyy V, Gehrke S, Adane B, et al. Targeting glutamine metabolism and redox state for leukemia therapy. Clin Cancer Res. 2019;25(13):4079\u201390.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"3535_CR347","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20236003","volume":"20","author":"JR Sillar","year":"2019","unstructured":"Sillar JR, Germon ZP, De Iuliis GN, Dun MD. The role of reactive oxygen species in acute myeloid leukaemia. Int J Mol Sci. 2019;20(23):6003.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3535_CR348","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab057","volume":"3","author":"A Cano-Galiano","year":"2021","unstructured":"Cano-Galiano A, Oudin A, Fack F, Allega M-F, Sumpton D, Martinez-Garcia E, et al. Cystathionine-\u03b3-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas. Neuro-Oncol Adv. 2021;3(1):vdab057.","journal-title":"Neuro-Oncol Adv"},{"key":"3535_CR349","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e40492","author":"J Hong","year":"2024","unstructured":"Hong J, Liu W, Xiao X, Gajendran B, Ben-David Y. Targeting pivotal amino acids metabolism for treatment of leukemia. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e40492.","journal-title":"Heliyon"},{"key":"3535_CR350","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2018.00243","volume":"6","author":"M Scalise","year":"2018","unstructured":"Scalise M, Galluccio M, Console L, Pochini L, Indiveri C. The human SLC7A5 (LAT1): the intriguing histidine\/large neutral amino acid transporter and its relevance to human health. Front Chem. 2018;6:243.","journal-title":"Front Chem"},{"issue":"24","key":"3535_CR351","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20246141","volume":"20","author":"L Bavaro","year":"2019","unstructured":"Bavaro L, Martelli M, Cavo M, Soverini S. Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update. Int J Mol Sci. 2019;20(24):6141.","journal-title":"Int J Mol Sci"},{"key":"3535_CR352","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0780-6","volume":"17","author":"S Soverini","year":"2018","unstructured":"Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17:1\u201315.","journal-title":"Mol Cancer"},{"key":"3535_CR353","doi-asserted-by":"publisher","first-page":"832263","DOI":"10.3389\/fimmu.2022.832263","volume":"13","author":"CG Atene","year":"2022","unstructured":"Atene CG, Fiorcari S, Mesini N, Alboni S, Martinelli S, Maccaferri M, et al. Indoleamine 2, 3-dioxygenase 1 mediates survival signals in chronic lymphocytic leukemia via kynurenine\/aryl hydrocarbon receptor-mediated MCL1 modulation. Front Immunol. 2022;13:832263.","journal-title":"Front Immunol"},{"issue":"11","key":"3535_CR354","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.3390\/cancers12113443","volume":"12","author":"MGC Mostazo","year":"2020","unstructured":"Mostazo MGC, Kurrle N, Casado M, Fuhrmann D, Alshamleh I, H\u00e4upl B, et al. Metabolic plasticity is an essential requirement of acquired tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Cancers. 2020;12(11):3443.","journal-title":"Cancers"},{"issue":"8","key":"3535_CR355","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.trecan.2021.02.004","volume":"7","author":"E Pranzini","year":"2021","unstructured":"Pranzini E, Pardella E, Paoli P, Fendt S-M, Taddei ML. Metabolic reprogramming in anticancer drug resistance: a focus on amino acids. Trends Cancer. 2021;7(8):682\u201399.","journal-title":"Trends Cancer"},{"key":"3535_CR356","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.767026","volume":"11","author":"M Soltani","year":"2021","unstructured":"Soltani M, Zhao Y, Xia Z, Ganjalikhani Hakemi M, Bazhin AV. The importance of cellular metabolic pathways in pathogenesis and selective treatments of hematological malignancies. Front Oncol. 2021;11:767026.","journal-title":"Front Oncol"},{"issue":"2","key":"3535_CR357","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/10428194.2013.804917","volume":"55","author":"X-Q Liu","year":"2014","unstructured":"Liu X-Q, Lu K, Feng L-L, Ding M, Gao J-M, Ge X-L, et al. Up-regulated expression of indoleamine 2, 3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration. Leuk Lymphoma. 2014;55(2):405\u201314.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"3535_CR358","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1182\/asheducation-2017.1.610","volume":"2017","author":"K Tarte","year":"2014","unstructured":"Tarte K. Role of the microenvironment across histological subtypes of NHL. Hematol Am Soc Hematol Educ Program book. 2014;2017(1):610\u20137.","journal-title":"Hematol Am Soc Hematol Educ Program book"},{"issue":"10","key":"3535_CR359","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105352","volume":"22","author":"T Watanabe","year":"2021","unstructured":"Watanabe T. The tumor microenvironment in follicular lymphoma: its pro-malignancy role with therapeutic potential. Int J Mol Sci. 2021;22(10):5352.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"3535_CR360","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1007\/s00018-021-03828-4","volume":"78","author":"A-A Mart\u00ed i L\u00edndez","year":"2021","unstructured":"Mart\u00ed i L\u00edndez A-A, Reith W. Arginine-dependent immune responses. Cell Mol Life Sci. 2021;78(13):5303\u201324.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"3535_CR361","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/ijc.30051","volume":"139","author":"L Fultang","year":"2016","unstructured":"Fultang L, Vardon A, De Santo C, Mussai F. Molecular basis and current strategies of therapeutic arginine depletion for cancer. Int J Cancer. 2016;139(3):501\u20139.","journal-title":"Int J Cancer"},{"issue":"6\u20137","key":"3535_CR362","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3109\/08820139.2012.680634","volume":"41","author":"P Raber","year":"2012","unstructured":"Raber P, Ochoa AC, Rodr\u00edguez PC. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest. 2012;41(6\u20137):614\u201334.","journal-title":"Immunol Invest"},{"issue":"7","key":"3535_CR363","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202300095","volume":"7","author":"JM Borkum","year":"2023","unstructured":"Borkum JM. The tricarboxylic acid cycle as a central regulator of the rate of aging: implications for metabolic interventions. Adv Biol. 2023;7(7):2300095.","journal-title":"Adv Biol"},{"issue":"21","key":"3535_CR364","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111384","volume":"25","author":"R Masnikosa","year":"2024","unstructured":"Masnikosa R, Cvetkovi\u0107 Z, Piri\u0107 D. Tumor biology hides novel therapeutic approaches to diffuse large B-cell lymphoma: a narrative review. Int J Mol Sci. 2024;25(21):11384.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3535_CR365","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3390\/medicina61030405","volume":"61","author":"C Colak","year":"2025","unstructured":"Colak C, Yagin FH, Algarni A, Algarni A, Al-Hashem F, Ardig\u00f2 LP. Untargeted lipidomic biomarkers for liver cancer diagnosis: a tree-based machine learning model enhanced by explainable artificial intelligence. Medicina (B Aires). 2025;61(3):405.","journal-title":"Medicina (B Aires)"},{"issue":"1","key":"3535_CR366","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201907022","volume":"219","author":"M Reina-Campos","year":"2019","unstructured":"Reina-Campos M, Diaz-Meco MT, Moscat J. The complexity of the serine glycine one-carbon pathway in cancer. J Cell Biol. 2019;219(1):e201907022.","journal-title":"J Cell Biol"},{"issue":"1","key":"3535_CR367","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40364-023-00487-4","volume":"11","author":"W Sun","year":"2023","unstructured":"Sun W, Liu R, Gao X, Lin Z, Tang H, Cui H, et al. Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers. Biomark Res. 2023;11(1):48.","journal-title":"Biomark Res"},{"issue":"1","key":"3535_CR368","doi-asserted-by":"publisher","first-page":"6235641","DOI":"10.1155\/2016\/6235641","volume":"2016","author":"B Marengo","year":"2016","unstructured":"Marengo B, Nitti M, Furfaro AL, Colla R, Ciucis CD, Marinari UM, et al. Redox homeostasis and cellular antioxidant systems: crucial players in cancer growth and therapy. Oxidative Med Cell Longev. 2016;2016(1):6235641.","journal-title":"Oxidative Med Cell Longev"},{"issue":"12","key":"3535_CR369","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.3390\/antiox11122444","volume":"11","author":"J Lee","year":"2022","unstructured":"Lee J, Roh J-L. SLC7A11 as a gateway of metabolic perturbation and ferroptosis vulnerability in cancer. Antioxidants. 2022;11(12):2444.","journal-title":"Antioxidants"},{"key":"3535_CR370","doi-asserted-by":"publisher","first-page":"886822","DOI":"10.3389\/fimmu.2022.886822","volume":"13","author":"B Yahsi","year":"2022","unstructured":"Yahsi B, Gunaydin G. Immunometabolism\u2013the role of branched-chain amino acids. Front Immunol. 2022;13:886822.","journal-title":"Front Immunol"},{"issue":"7","key":"3535_CR371","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23074022","volume":"23","author":"A Dimou","year":"2022","unstructured":"Dimou A, Tsimihodimos V, Bairaktari E. The critical role of the branched chain amino acids (BCAAs) catabolism-regulating enzymes, branched-chain aminotransferase (BCAT) and branched-chain \u03b1-keto acid dehydrogenase (BCKD), in human pathophysiology. Int J Mol Sci. 2022;23(7):4022.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3535_CR372","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","volume":"128","author":"M Bolzoni","year":"2016","unstructured":"Bolzoni M, Chiu M, Accardi F, Vescovini R, Airoldi I, Storti P, et al. Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. Blood. 2016;128(5):667\u201379.","journal-title":"Blood"},{"key":"3535_CR373","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00726-011-0867-5","volume":"42","author":"M Conrad","year":"2012","unstructured":"Conrad M, Sato H. The oxidative stress-inducible cystine\/glutamate antiporter, system xc\u2013: cystine supplier and beyond. Amino Acids. 2012;42:231\u201346.","journal-title":"Amino Acids"},{"issue":"8","key":"3535_CR374","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599\u2013620.","journal-title":"Protein Cell"},{"issue":"8","key":"3535_CR375","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s11864-023-01104-0","volume":"24","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Hu B, Guo Y, Zhang D, Zhao Y, Chen Y, et al. Targeting glutamine metabolism as an attractive therapeutic strategy for acute myeloid leukemia. Curr Treat Options Oncol. 2023;24(8):1021\u201335.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"3535_CR376","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030190","volume":"14","author":"K Mahmood","year":"2021","unstructured":"Mahmood K, Emadi A. 1-C metabolism\u2014serine, glycine, folates\u2014in acute myeloid leukemia. Pharmaceuticals. 2021;14(3):190.","journal-title":"Pharmaceuticals"},{"key":"3535_CR377","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01480","volume":"9","author":"M Chiu","year":"2020","unstructured":"Chiu M, Taurino G, Bianchi MG, Kilberg MS, Bussolati O. Asparagine synthetase in cancer: beyond acute lymphoblastic leukemia. Front Oncol. 2020;9:1480.","journal-title":"Front Oncol"},{"issue":"7","key":"3535_CR378","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/00005768-200007000-00005","volume":"32","author":"RA Bassit","year":"2000","unstructured":"Bassit RA, Sawada LA, Bacurau RFP, Navarro F, Rosa L. The effect of BCAA supplementation upon the immune response of triathletes. Med Sci Sports Exerc. 2000;32(7):1214\u20139.","journal-title":"Med Sci Sports Exerc"},{"issue":"16","key":"3535_CR379","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168738","volume":"22","author":"L Di Martino","year":"2021","unstructured":"Di Martino L, Tosello V, Peroni E, Piovan E. Insights on metabolic reprogramming and its therapeutic potential in acute leukemia. Int J Mol Sci. 2021;22(16):8738.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3535_CR380","first-page":"491","volume":"2005","author":"DS Rosenthal","year":"2005","unstructured":"Rosenthal DS, Dean-Clower E. Integrative medicine in hematology\/oncology: benefits, ethical considerations, and controversies. ASH Educ Program Book. 2005;2005(1):491\u20137.","journal-title":"ASH Educ Program Book"},{"key":"3535_CR381","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_237987","author":"M Datta","year":"2019","unstructured":"Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2019. https:\/\/doi.org\/10.1200\/EDBK_237987.","journal-title":"American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting"},{"issue":"1","key":"3535_CR382","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01195-7","volume":"15","author":"DC Joshi","year":"2024","unstructured":"Joshi DC, Sharma A, Prasad S, Singh K, Kumar M, Sherawat K, et al. Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy. Discover Oncol. 2024;15(1):342.","journal-title":"Discover Oncol"},{"issue":"2","key":"3535_CR383","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O\u2019Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140(2):112\u201320.","journal-title":"Blood"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03535-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03535-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03535-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:02:49Z","timestamp":1758052969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03535-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":383,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3535"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03535-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not involve any clinical trial or animal models.Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and\u00a0consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1687"}}